WO2004085505A2 - Long acting biologically active conjugates - Google Patents
Long acting biologically active conjugates Download PDFInfo
- Publication number
- WO2004085505A2 WO2004085505A2 PCT/US2004/008847 US2004008847W WO2004085505A2 WO 2004085505 A2 WO2004085505 A2 WO 2004085505A2 US 2004008847 W US2004008847 W US 2004008847W WO 2004085505 A2 WO2004085505 A2 WO 2004085505A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- complex
- alkyl
- phe
- peptide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 373
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 250
- 125000005647 linker group Chemical group 0.000 claims abstract description 184
- 108090000623 proteins and genes Chemical group 0.000 claims abstract description 146
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 144
- 102000009027 Albumins Human genes 0.000 claims abstract description 135
- 108010088751 Albumins Proteins 0.000 claims abstract description 135
- 239000002461 renin inhibitor Substances 0.000 claims abstract description 96
- 229940086526 renin-inhibitors Drugs 0.000 claims abstract description 89
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 86
- 238000001727 in vivo Methods 0.000 claims abstract description 61
- 241000700605 Viruses Species 0.000 claims abstract description 37
- 241000282414 Homo sapiens Species 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 230000009385 viral infection Effects 0.000 claims abstract description 19
- 208000036142 Viral infection Diseases 0.000 claims abstract description 14
- 230000009471 action Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 189
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 169
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 169
- 229910052757 nitrogen Inorganic materials 0.000 claims description 165
- 229910052739 hydrogen Inorganic materials 0.000 claims description 152
- 229910052740 iodine Inorganic materials 0.000 claims description 146
- 235000018102 proteins Nutrition 0.000 claims description 141
- 125000000217 alkyl group Chemical group 0.000 claims description 119
- 229910052700 potassium Inorganic materials 0.000 claims description 119
- 229910052720 vanadium Inorganic materials 0.000 claims description 116
- 235000001014 amino acid Nutrition 0.000 claims description 113
- 150000001413 amino acids Chemical class 0.000 claims description 113
- 239000000203 mixture Substances 0.000 claims description 97
- -1 iodo- Chemical class 0.000 claims description 82
- 229910052727 yttrium Inorganic materials 0.000 claims description 78
- 229910052717 sulfur Inorganic materials 0.000 claims description 74
- 210000004369 blood Anatomy 0.000 claims description 55
- 239000008280 blood Substances 0.000 claims description 55
- 230000000694 effects Effects 0.000 claims description 54
- 229910052731 fluorine Inorganic materials 0.000 claims description 50
- 239000012503 blood component Substances 0.000 claims description 46
- 229910052721 tungsten Inorganic materials 0.000 claims description 42
- 125000000524 functional group Chemical group 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 108090000783 Renin Proteins 0.000 claims description 32
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 32
- 102100028255 Renin Human genes 0.000 claims description 31
- 230000001225 therapeutic effect Effects 0.000 claims description 31
- 229910052698 phosphorus Inorganic materials 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 229910052722 tritium Inorganic materials 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 22
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 20
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 20
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 18
- 238000003776 cleavage reaction Methods 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 18
- 230000007017 scission Effects 0.000 claims description 18
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 150000008064 anhydrides Chemical class 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 239000000816 peptidomimetic Substances 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 150000001299 aldehydes Chemical class 0.000 claims description 12
- 229910052805 deuterium Inorganic materials 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 108091005573 modified proteins Proteins 0.000 claims description 12
- 238000007911 parenteral administration Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- ZFEAMMNVDPDEGE-LGRGJMMZSA-N tifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(C)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 ZFEAMMNVDPDEGE-LGRGJMMZSA-N 0.000 claims description 12
- 230000007704 transition Effects 0.000 claims description 12
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 150000001350 alkyl halides Chemical class 0.000 claims description 11
- 150000001541 aziridines Chemical class 0.000 claims description 11
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 11
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims description 10
- ZYJSTSMEUKNCEV-UHFFFAOYSA-N 3-diazo-1-diazonioprop-1-en-2-olate Chemical class [N-]=[N+]=CC(=O)C=[N+]=[N-] ZYJSTSMEUKNCEV-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 150000003926 acrylamides Chemical class 0.000 claims description 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 10
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 10
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical class ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 10
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 claims description 10
- 150000002118 epoxides Chemical class 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 10
- 229940072221 immunoglobulins Drugs 0.000 claims description 10
- 150000002825 nitriles Chemical class 0.000 claims description 10
- 150000002902 organometallic compounds Chemical class 0.000 claims description 10
- 150000007659 semicarbazones Chemical class 0.000 claims description 10
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium group Chemical group [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims description 10
- GWIKYPMLNBTJHR-UHFFFAOYSA-M thiosulfonate group Chemical group S(=S)(=O)[O-] GWIKYPMLNBTJHR-UHFFFAOYSA-M 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 8
- 102000007562 Serum Albumin Human genes 0.000 claims description 8
- 108010071390 Serum Albumin Proteins 0.000 claims description 8
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 8
- 150000001718 carbodiimides Chemical class 0.000 claims description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 102000035118 modified proteins Human genes 0.000 claims description 8
- 230000000144 pharmacologic effect Effects 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 150000007970 thio esters Chemical class 0.000 claims description 7
- MDNSLPICAWKNAG-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)C=CC1=O MDNSLPICAWKNAG-UHFFFAOYSA-N 0.000 claims description 6
- CXGYVVWOYNOMBX-UHFFFAOYSA-N 3-benzoylpyrrolidine-2,5-dione;pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.C=1C=CC=CC=1C(=O)C1CC(=O)NC1=O CXGYVVWOYNOMBX-UHFFFAOYSA-N 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 6
- NXVYSVARUKNFNF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) 2,3-dihydroxybutanedioate Chemical compound O=C1CCC(=O)N1OC(=O)C(O)C(O)C(=O)ON1C(=O)CCC1=O NXVYSVARUKNFNF-UHFFFAOYSA-N 0.000 claims description 6
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 239000012948 isocyanate Substances 0.000 claims description 6
- 150000002513 isocyanates Chemical class 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940080818 propionamide Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 6
- 150000004799 α-ketoamides Chemical class 0.000 claims description 6
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims description 5
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 5
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 102000008857 Ferritin Human genes 0.000 claims description 5
- 108050000784 Ferritin Proteins 0.000 claims description 5
- 238000008416 Ferritin Methods 0.000 claims description 5
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 claims description 5
- 102000005963 steroid binding proteins Human genes 0.000 claims description 5
- 108020003178 steroid binding proteins Proteins 0.000 claims description 5
- NPYRCTHITOIVLV-VEUFVCKOSA-N (2r)-1-[(2s)-2-acetamido-3-(1h-imidazol-5-yl)propanoyl]-n-[(2s)-1-[[(2s)-1-[[(2s,3s)-5-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-cyclohexyl-3-hydroxy-5-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropa Chemical compound C([C@@H]([C@@H](O)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H]1N(CCC1)C(=O)[C@H](CC=1N=CNC=1)NC(C)=O)C1CCCCC1 NPYRCTHITOIVLV-VEUFVCKOSA-N 0.000 claims description 4
- 108010032976 Enfuvirtide Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
- 235000014666 liquid concentrate Nutrition 0.000 claims description 4
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 4
- YLFGKFNAVPVWDW-AJEFLBOZSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-2-methylbutanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]-n-[(2s)-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-(1h-imidazol Chemical compound C([C@H](NC(=O)[C@@](C)(N)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)NC(CC(C)C)C(O)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CNC=N1 YLFGKFNAVPVWDW-AJEFLBOZSA-N 0.000 claims description 3
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 2
- DLAHCJHYEAZDLE-VRYQDWSQSA-N methyl (2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(3s,4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino] Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC=1C=CC=CC=1)C1=CN=CN1 DLAHCJHYEAZDLE-VRYQDWSQSA-N 0.000 claims description 2
- 108010037251 peptide T1249 Proteins 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- AIRMFERKNRDUKD-PVGXKDMPSA-N (2s)-6-amino-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propano Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AIRMFERKNRDUKD-PVGXKDMPSA-N 0.000 claims 2
- 108010026906 renin inhibitory peptide Proteins 0.000 claims 2
- XDEHMKQLKPZERH-BYPYZUCNSA-N (2s)-2-amino-3-methylbutanamide Chemical compound CC(C)[C@H](N)C(N)=O XDEHMKQLKPZERH-BYPYZUCNSA-N 0.000 claims 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 61
- 230000003612 virological effect Effects 0.000 abstract description 28
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 19
- 230000004071 biological effect Effects 0.000 abstract description 15
- 229920002521 macromolecule Polymers 0.000 abstract description 14
- 229940125777 fusion inhibitor Drugs 0.000 abstract description 8
- 241000712079 Measles morbillivirus Species 0.000 abstract description 6
- 241000713311 Simian immunodeficiency virus Species 0.000 abstract description 6
- 241000725643 Respiratory syncytial virus Species 0.000 abstract description 4
- 230000001268 conjugating effect Effects 0.000 abstract description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract description 3
- 239000000562 conjugate Substances 0.000 description 107
- 238000006243 chemical reaction Methods 0.000 description 67
- 239000003814 drug Substances 0.000 description 66
- 102000004196 processed proteins & peptides Human genes 0.000 description 65
- 229940079593 drug Drugs 0.000 description 55
- 239000000243 solution Substances 0.000 description 55
- 239000003795 chemical substances by application Substances 0.000 description 52
- 238000002360 preparation method Methods 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 239000013543 active substance Substances 0.000 description 35
- 230000021615 conjugation Effects 0.000 description 34
- 239000003443 antiviral agent Substances 0.000 description 32
- 210000002381 plasma Anatomy 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 102000004506 Blood Proteins Human genes 0.000 description 28
- 108010017384 Blood Proteins Proteins 0.000 description 28
- 239000000306 component Substances 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000027455 binding Effects 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 230000004927 fusion Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 102000035195 Peptidases Human genes 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 235000019419 proteases Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 229920001184 polypeptide Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- 206010059866 Drug resistance Diseases 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 125000003729 nucleotide group Chemical class 0.000 description 8
- 239000000863 peptide conjugate Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 238000011225 antiretroviral therapy Methods 0.000 description 7
- 229940124522 antiretrovirals Drugs 0.000 description 7
- 239000003903 antiretrovirus agent Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229910052777 Praseodymium Inorganic materials 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 230000000798 anti-retroviral effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003124 biologic agent Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108091005601 modified peptides Proteins 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 102400000344 Angiotensin-1 Human genes 0.000 description 5
- 101800000734 Angiotensin-1 Proteins 0.000 description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 239000002835 hiv fusion inhibitor Substances 0.000 description 5
- 229960001936 indinavir Drugs 0.000 description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 239000005871 repellent Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- OIWXLVBZDMAARO-UHFFFAOYSA-N 2-decylsulfanylethanamine Chemical compound CCCCCCCCCCSCCN OIWXLVBZDMAARO-UHFFFAOYSA-N 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 101000579218 Homo sapiens Renin Proteins 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 206010066901 Treatment failure Diseases 0.000 description 4
- VORIUEAZEKLUSJ-UHFFFAOYSA-M [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 VORIUEAZEKLUSJ-UHFFFAOYSA-M 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000005923 long-lasting effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940123150 Chelating agent Drugs 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229960003804 efavirenz Drugs 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000002185 fusiogenic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003791 organic solvent mixture Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- MSTPNDZQVGSTET-UHFFFAOYSA-M sodium;2-anilino-6-sulfanylidene-1h-1,3,5-triazine-4-thiolate Chemical compound [Na+].N1C(=S)N=C([S-])N=C1NC1=CC=CC=C1 MSTPNDZQVGSTET-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YZHIXLCGPOTQNB-UHFFFAOYSA-N 2-methyl-furan-3-carbothioic acid [4-chloro-3-(3-methyl-but-2-enyloxy)-phenyl]-amide Chemical compound C1=C(Cl)C(OCC=C(C)C)=CC(NC(=S)C2=C(OC=C2)C)=C1 YZHIXLCGPOTQNB-UHFFFAOYSA-N 0.000 description 2
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101710101803 DNA-binding protein J Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150048348 GP41 gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- BINXAIIXOUQUKC-UIPNDDLNSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]-1-phenylbutan-2-yl]carbamate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)CC1=CC=CC=C1 BINXAIIXOUQUKC-UIPNDDLNSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 238000002832 anti-viral assay Methods 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 2
- AYXBAIULRDEVAS-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;iodide Chemical compound [I-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 AYXBAIULRDEVAS-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000799 fusogenic effect Effects 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940124524 integrase inhibitor Drugs 0.000 description 2
- 239000002850 integrase inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 2
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- IFVRMXRXQKVDCE-BTQAAEOHSA-N tert-butyl (2s)-2-[[(2s)-1-[[(2s)-1-[[4-amino-5-hydroxy-2-methyl-7-[[(2s,3s)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]amino]-7-oxoheptyl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidine-1-car Chemical compound C([C@@H](C(=O)NCC(C)CC(N)C(O)CC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC=1N=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C)C1=CNC=N1 IFVRMXRXQKVDCE-BTQAAEOHSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000004149 thio group Chemical group *S* 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000024275 uncoating of virus Effects 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229940120938 zidovudine and lamivudine Drugs 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical class CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- KYRSNWPSSXSNEP-ZRTHHSRSSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 KYRSNWPSSXSNEP-ZRTHHSRSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- BEMROAADXJFLBI-UHFFFAOYSA-N 1-(cyclopent-3-en-1-ylmethyl)-6-(3,5-dimethylbenzoyl)-5-ethylpyrimidine-2,4-dione Chemical compound C1C=CCC1CN1C(=O)NC(=O)C(CC)=C1C(=O)C1=CC(C)=CC(C)=C1 BEMROAADXJFLBI-UHFFFAOYSA-N 0.000 description 1
- QBRCQKYEBCOZPI-HCWSKCQFSA-N 1-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-iodyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(I(=O)=O)N1C(=O)NC(=O)C=C1 QBRCQKYEBCOZPI-HCWSKCQFSA-N 0.000 description 1
- HMWAJFNEGAJETK-UHFFFAOYSA-N 1-[6-(dimethylamino)naphthalen-2-yl]prop-2-en-1-one Chemical compound C1=C(C(=O)C=C)C=CC2=CC(N(C)C)=CC=C21 HMWAJFNEGAJETK-UHFFFAOYSA-N 0.000 description 1
- UEUPDYPUTTUXLJ-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride Chemical compound Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 UEUPDYPUTTUXLJ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- LHYWVHAYHFLMQK-UHFFFAOYSA-N 2-(cyclohexen-1-ylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NC1=CCCCC1 LHYWVHAYHFLMQK-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- OEEHSSKRJOGQMP-UHFFFAOYSA-N 2-[(2-carbamoylphenyl)disulfanyl]benzamide Chemical class NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(N)=O OEEHSSKRJOGQMP-UHFFFAOYSA-N 0.000 description 1
- XQPYRJIMPDBGRW-UHFFFAOYSA-N 2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCC(=O)O)C3=CC=CC=C3C2=C1 XQPYRJIMPDBGRW-UHFFFAOYSA-N 0.000 description 1
- BLUJRJMLDHEMRX-BMNRKXRESA-N 2-[[2-hydroxy-5-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1\N=C\c2ccc(O)c(c2)C(c3ccc(O)cc3)c4cc(\C=N\n5nnnc5C)ccc4O BLUJRJMLDHEMRX-BMNRKXRESA-N 0.000 description 1
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- BJEVMXQIEZQIHC-UHFFFAOYSA-N 2-iodo-n-(2',4',5',7'-tetrabromo-3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)acetamide Chemical compound O1C(=O)C2=CC(NC(=O)CI)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 BJEVMXQIEZQIHC-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- NRQJIAVOKMKUOR-UHFFFAOYSA-N 2-piperazin-1-ylquinazoline Chemical class C1CNCCN1C1=NC=C(C=CC=C2)C2=N1 NRQJIAVOKMKUOR-UHFFFAOYSA-N 0.000 description 1
- IUTPJBLLJJNPAJ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)C=CC1=O IUTPJBLLJJNPAJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XDGRAWWEIOPNRC-UHFFFAOYSA-N 3-hydroxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OS(=O)(=O)C1(O)CC(=O)NC1=O XDGRAWWEIOPNRC-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- OZDVVQOUJDQIKT-UHFFFAOYSA-N 4-[2-[[4-(2-aminohexanoylamino)-3-hydroxy-6-methylheptanoyl]amino]propanoylamino]-3-hydroxy-6-methylheptanoic acid Chemical compound CCCCC(N)C(=O)NC(CC(C)C)C(O)CC(=O)NC(C)C(=O)NC(CC(C)C)C(O)CC(O)=O OZDVVQOUJDQIKT-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
- ALEVUYMOJKJJSA-UHFFFAOYSA-N 4-hydroxy-2-propylbenzoic acid Chemical class CCCC1=CC(O)=CC=C1C(O)=O ALEVUYMOJKJJSA-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- VOJOOGPALCATLT-ZFQBPCNVSA-N 5-[1-(3-carboxy-5-chloro-4-hydroxyphenyl)-4-[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-hydroxybenzoic acid Chemical class C([C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)CC=C(C=1C=C(C(O)=C(Cl)C=1)C(O)=O)C1=CC(Cl)=C(O)C(C(O)=O)=C1 VOJOOGPALCATLT-ZFQBPCNVSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000005234 Adenosylhomocysteinase Human genes 0.000 description 1
- 108020002202 Adenosylhomocysteinase Proteins 0.000 description 1
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000004156 Azodicarbonamide Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 229940127463 Enzyme Inducers Drugs 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000732617 Homo sapiens Angiotensinogen Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010022078 Injection site inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FTSCEGKYKXESFF-LXTVHRRPSA-N N-nonyldeoxynojirimycin Chemical compound CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO FTSCEGKYKXESFF-LXTVHRRPSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000579222 Rattus norvegicus Renin Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010051259 Therapy naive Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940116731 Uricosuric agent Drugs 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- XLPGURCDSRIXFL-JGVFFNPUSA-N [(2s,5r)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](COP(O)(O)=O)O1 XLPGURCDSRIXFL-JGVFFNPUSA-N 0.000 description 1
- FDLQZKYLHJJBHD-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanamine Chemical group NCC1=CC=CC(CN)=C1 FDLQZKYLHJJBHD-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical group C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229950005846 amdoxovir Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000003374 anti-dyskinetic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002364 anti-haemorrhagic effect Effects 0.000 description 1
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002558 anti-leprotic effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000539 anti-peristaltic effect Effects 0.000 description 1
- 230000003473 anti-pneumocystis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002050 anti-rickettsial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 229940124343 antiamebic agent Drugs 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- XOZUGNYVDXMRKW-AATRIKPKSA-N azodicarbonamide Chemical compound NC(=O)\N=N\C(N)=O XOZUGNYVDXMRKW-AATRIKPKSA-N 0.000 description 1
- 235000019399 azodicarbonamide Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000007658 benzothiadiazines Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005515 capillary zone electrophoresis Methods 0.000 description 1
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 1
- 229950008230 capravirine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000002779 cholinesterase reactivator Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 108060002021 cyanovirin N Proteins 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940124569 cytoprotecting agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 229940124784 gp41 inhibitor Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000004797 ketoamides Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229950005339 lobucavir Drugs 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229950008798 mozenavir Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002863 oxytocic agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- OTYNBGDFCPCPOU-UHFFFAOYSA-N phosphane sulfane Chemical compound S.P[H] OTYNBGDFCPCPOU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229960000471 pleconaril Drugs 0.000 description 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000007153 proteostasis deficiencies Diseases 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 108010003641 statine renin inhibitory peptide Proteins 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BESDYXOPYOAWRZ-UHFFFAOYSA-N temacrazine Chemical compound C12=C3C(=O)C4=CC=CC=C4N1N=NC2=CC=C3NCCCN(CC1)CCN1CCCNC1=CC=C2N=NN3C4=CC=CC=C4C(=O)C1=C32 BESDYXOPYOAWRZ-UHFFFAOYSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000003488 thyrotrophic effect Effects 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000000990 untiurolithic effect Effects 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to biologically active compounds that may be used to react with proteins, such as albumin, to form covalent linked complexes wherein the 5 resulting complexes exhibit a desired bioligical activity in vivo.
- the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein, hi one embodiment, the protein is a blood protein such as albumin, or HSA. In another embodiment, the protein is recombinant HSA.
- the complexes are prepared by conjugating a biologically active o moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein.
- the complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule.
- the compounds and complexes of the present invention are isolated and 5 purified.
- the invention also provides methods for achieiving a desired biological effect in vivo, comprising administering to the bloodstream of a mammalian host the novel isolated complexes of the present invention.
- the invention also provides compounds, including nucleosides, nucleoside analogs, nucleotides, nucleotide analogs, polypeptides, polypeptide derivatives, o peptidomimetic compounds and their bioconjugated forms that are inhibitors of virus infections.
- the invention also provides methods for administering bioconjugated forms of these inhibitors having an extended duration of action for the treatment of virus infections, including multidrug-resistant virus infections.
- the invention provides compounds and their bioconjugated forms that inhibit human immunodeficiency viruses (HIV), and methods for administering bioconjugated forms of inhibitors that provide a prolonged duration of action for the treatment of HIV infections, including multidrug-resistant HTV infections (mdrHIV).
- HIV human immunodeficiency viruses
- active peptide and protein therapeutics useful for administration to a mammalian host exhibit poor pharmacokinetic profiles, and are often rapidly metabolized and cleared by the mammalian system before the peptide or protein can bind to a specific target.
- the biologically active agents are susceptible to enzyme degradation and clearance.
- certain active agents must be administered more frequently which result in undesired large fluctuations in the blood plasma levels of the agent can lead to a variety of adverse side reactions and/or diminished efficacy.
- the active agent must be able to be transported to the active site or must be administered directly to the target site without significant loss of biological activity.
- the majority of drugs are administered orally.
- the administered dosage requires that the drug be administered repetitively to maintain a therapeutic level and the rapid decrease in blood levels over time often results in initial levels that exceeds the desired therapeutic levels.
- Various technological approaches have been designed to avoid these problems, including the administration of biologically active agents by mechanical systems such as pumps, controlled release or slow release tablets and capsules, depots and related technologies.
- Therapeutic agents that are administered by injections encounter similar problems relating to their limited lifetime in vivo. Moreover, repetitive injections are inconvenient and highly undesirable. Therefore, there is a need for new methods that allow for ease of administration of biologically active agents into the bloodstream and that maintain effective levels of the therapeutic agents for an extended period of time in vivo.
- AIDS Acquired immune deficiency syndrome
- the AIDS virus was first identified in 1983. It has been known by several names and acronyms. It was originally the third known T-lymphocyte virus (HTLV- 5 TTT), and it has the capacity to replicate within cells of the immune system, causing profound cell destruction and impairment of immunity.
- the AIDS virus is a retrovirus, which is family of viruses that use reverse transcriptase during their replication. This particular retrovirus is also known as lymphadenopathy-associated virus (LAV), ADDS-related virus (ARV) and, most recently, as human o immunodeficiency virus (HIV).
- LAV lymphadenopathy-associated virus
- ARV ADDS-related virus
- HAV human o immunodeficiency virus
- HIV is a member of the lentivirus family of retroviruses, which mcludes simian immunodeficiency virus (SIV), and numerous other retroviruses that cause immunodeficency diseases in mammals.
- SIV simian immunodeficiency virus
- HTV-2 Two distinct types of HIV have been 5 described to date, namely HIV-l and HTV-2, although infection with HTV-1 is more common worldwide.
- the acronym HTV will be used herein to refer to all HIV-l viruses generically, unless otherwise noted.
- HTV-1 is further divided into three groups: major (M), outlier (O), and new (N).
- M major
- O outlier
- N new
- Most HTV-1 isolates to date belong to one often distinct clades, or subtypes, of the M group.
- the M group subtypes are o represented by the letters A-J.
- Subtype B is the most common in the US and Europe.
- subtype C accounts for almost 50% of HTV worldwide, and is most common in Africa. All subtypes are present in Africa, with non-C clades tending to be cluster in distinct geographical regions. Subtype identification is usually determined by sequencing of the env gene, and comparison of the gp41 sequences, which give a subtype "fingerprint".
- HTV primarily infects CD4-bearing helper/inducer T-cells, and can also infect other cells that express the CD4 glycoprotein at the membrane surface. Recent evidence has shown that the co-localization of certain chemokine receptors at the cell surface is essential for efficient viral infection. HTV is cytopathic to o CD4+ lymphocytes, and their numbers steadily decline of over a period of years, resulting in a severely compromised immune system. HTV infection can also result in neurological deterioration and dementia. Unless treated with effective chemotherapy, HTV infection is almost always fatal, and leads to death from opportunistic infections, cancer or neurodegenerative disease. 5 The HTV-1 genome contains at least nine different genes.
- gag coding for structural proteins
- pol coding for the viral enzymes - protease, reverse transcriptase and integrase
- env coding for the envelope glycoproteins
- gag and pol regions of the genome encode polycistronic messenger o RNAs which are translated into large polyprotein precursors.
- the viral polyproteins are subsequently cleaved into mature structural proteins and enzymes by a viral- encoded protease that is, itself, a product of the pol gene.
- the two Env proteins, gpl20 and gp41 are cleaved from a larger precursor (gpl60) by a cellular enzyme.
- Other HTV-1 gene products e.g., Tat, Rev, Vpr, and Nef, intervene to 5 regulate the virus life cycle. Nef also affects particle infectivi ⁇ y.
- the gene products Vif and Vpu function in virus infectivity and virus particle maturation, respectively.
- the viral genome is flanked at each end by long terminal repeat sequences (LTRs).
- LTRs contain binding sites for cellular proteins that are able to activate transcription and are also under the control of viral signals.
- the complex regulation o of HTV allows the virus to establish latency, then respond rapidly to various signals and synthesize high levels of viral proteins and virions, leading to the production and release of large numbers of progeny virus, the subsequent destruction of the infected cell, and the re-infection of large numbers of healthy CD4+ lymphocytes.
- antiretroviral chemotherapeutics developed in response to the need for agents effective against retroviruses, in particular HTV.
- sixteen antiretroviral agents were approved by the FDA for treatment of HTV/ATDS. While there are many ways, in principle, in which an agent can exhibit antiretroviral activity, all of these agents inhibit either the viral reverse transcriptase, or the viral protease.
- Highly active antiretroviral therapy refers to a variety of drug 'cocktails', or combinations of three or more antiretroviral agents, that can potently suppress viral replication and prevent or delay the onset of AIDS (Mitsuya, H., and J. Erickson. 1999.
- NRTIs nucleoside reverse transcriptase inhibitors
- NRTIs non-nucleoside reverse transcriptase inhibitors
- Pro protease inhibitors
- the initial strain of drug resistant HTV that is selected depends on the particular drug regimen, and often requires the replacement of one drug by o another of the same class. However, over time the continued selection of new strains with multiple mutations often leads to class-specific drug-resistance and, eventually, to complete treatment failure.
- Cross-resistance to drugs of the same class is spreading at an alarmingly high rate (Erickson, et al, ADDS, 13:S189, (1999); Gulnik, et al, Vitam. Horm., 58:213 (2000); Menendez-Arias, et al, Trends 5 Pharmacol. Sci., 23:381 (2002)).
- HAART toxicity Some of the more serious side effects associated with HAART toxicity include liver problems, heart disease, and lipodystrophy (Chen, et al, J. Clin. Endocrinol. Metab., 87:4845 (2002); Holstein, et al, Exp. Clin. Endocrinol. Diabetes 109:389 (2001)).
- the combination of resistance and side effects result in poor adherence to drug regimens and, ultimately, to treatment failure rates of between 40-45% (Wit, et al, J. Infect. Dis. 179:790 (1999); Fatkenheuer, et al, ATDS 11:F113 (1997); Lucas, et al, Ann. Intern. Med. 131:81 (1999); Chen, et al, 41st hitl Conf Antimicrob. Agents Chemother., Abstract 1-1914 (2001)).
- a substantial number of patients currently taking HAART will soon run out of therapeutic options.
- the initial step in HTV infection of a CD4-bearing cell is the recognition of the CD4 receptor by the HTV gpl20 envelope protein, which is non-covalently associated with the viral membrane through the viral membrane-bound HTV gp41 envelope protein.
- the gp41 protein, or "fusion protein” contains several "fusiogenic” domains, including a fusion peptide and two self-associating helix- 5 forming segments (the "N-helix” and "C-helix”).
- gpl20 protein Recognition and binding of gpl20 protein to the CD4 and chemokine receptors triggers the unmasking of the fusiogenic domains, the insertion of gp41 into the cell membrane, and the self-association of the two helix-forming segments into a "hairpin" structure.
- the formation of the hairpin structure of gp41 is believed 0 to be an essential step in the fusion of the viral and cell membranes, and is a slow process, requiring up to 30 min to complete.
- Membrane fusion events while commonplace in normal cellular processes, are also involved in a variety of disease states, including, for example, the entry of enveloped viruses into cells, and the aberrant fusion of virus-infected cells with healthy cells, leading to the formation of 5 syncytia, and the subsequent clearance, or death, of the cells.
- Peptides and small molecules are known to inhibit or otherwise disrupt membrane fusion-associated events, including, for example, inhibiting retroviral infection of target cells.
- polypeptides which inhibit the HTV infection of CD4 cells by interfering with the fusion reaction.
- anti- o fusiogenic peptides are derived from the native amino acid sequence of either of the two helix-forming segments of gp41 (Jiang et al, Curr. Pharmaceut. Design 8:563 (2002)).
- Polypeptides consisting of sequences from either the N- or C-helix- forming regions of gp41 exhibit antiviral activity in cell culture assays.
- X-ray crystal structures and NMR solution structures of various isolated, recombinant 5 forms of HTV-1, HTV-2 and STV fusion proteins show that they all form trimers that with an anti-parallel, helical bundle-type fold.
- the bundles consist of three sets of hairpins, each of which is formed by the antiparallel association between the two helix-forming segments from a single protein chain.
- the hairpins are arranged in such a way that the first, or N-terminal, helical segments are associated in a tiimeric o inner bundle, and the second, or C-terminal, segments interact with the grooves formed by two adjacent N-terminal helices.
- the hairpin structure appears to be a consequence of assembly into the quaternary structure of the trimer, as opposed to being the fundamental building block of the trimer.
- Peptides from the C-terminal and N-terminal heptad repeat regions including DPI 78 (Wild, et al., Proc. Natl. Acad. Sci. USA, 91:9770 (1994)), also 5 known as T-20, C34 (Chan, et al, Proc. Natl. Acad. Sci. USA, 95:15613 (1998)), and DP 107 exhibit potent antiviral activity.
- T-20 a 34-residue peptide, has been shown to effectively lower viral load in drug- experienced patients. This validates gp41 as a promising target for the development of new anti-HTV drugs.
- T-20 has a short half-life of 1.8 hours (Kilby, et al, Nat. Med., 4:1302 (1998)), and needs to be administered by subcutaneous injection, twice a o day. Injection-site inflammation is a common side-effect reaction, and the drug formulation and manufacturing challenges result in high cost of treatment. T-20 is also rendered ineffective through the selection of a number of single mutations that lead to drug resistance both in vitro and in vivo.
- T-1249 is in Phase TJ clinical trials. This compound is an even 5 longer peptide than T-20. Its chief advantage is that it is more potent and has a longer half-life than T-20. However, T-1249 still suffers from the requirement for daily injection, and drug resistant mutants are readily selected using this drug .
- both T-20 and T-1249 must be administered intravenously or subcutaneously, and, both exhibit a short half-life in vivo, primarily o due to rapid serum clearance and peptidase and protease activity. These pharmacological limitations reduce the therapeutic effectiveness of these agents, while at the same time resulting in a high cost of freatment.
- C34 like T-20 and T-1249, also suffers from a short half-life in vivo, primarily due to rapid serum clearance and peptidase and protease activity. This in 5 turn greatly reduces its effective anti-viral activity.
- Inhibitors with prolonged in vivo half-lives that possess durable suppression of viral replication in vivo are defined as "long-lasting" inhibitors.
- resistance-repellent inhibitors and long-lasting inhibitors each represent clear and unique advantages in the treatment of HTV/ATDS. It should also be recognized that the combination of these two properties in a single agent would represent a revolutionary advance in antiviral therapy. Inhibitors that are both resistance-repellent and long-lasting are defined as broad spectrum durable inhibitors. Serum Albumin as a Prodrug:
- a doxorubicin-albumin conjugate has been disclosed as an antineoplastic prodrug agent. (F. Kratz et al, J. Med. Chem. 2000, 43, 1253-1256). However, the conjugate was prepared with an acid sensitive linker that allows the drug to be released at the low pH values present in lysosomes and indosomes of tumor cells. The preparation of the conjugate was designed to avoid the ex vivo synthesis and characterization of drug albumin conjugate which was considered to be costly.
- the present invention relates to biologically active compounds that may be used to react with proteins to form covalently linked complexes wherein the resulting complexes are found to exhibit desirable biological activities in vivo. More specifically, the complexes are isolated complexes comprising a compound, such as an antiviral compound and a linking group, and the blood component is a protein such as albumin.
- the present invention also provides methods for achieving a desired activity in vivo, such as anti-viral activity, comprising administering to the bloodstream of a mammalian host the novel isolated complexes of the present invention.
- a pharmaceutical composition comprising a purified conjugate, such as an anti-viral complex, according to the present invention as an active ingredient.
- Pharmaceutical compositions according to the invention may optionally comprise 0.001%- 100% of one or more conjugates, such as anti-viral complexes, of this invention.
- These pharmaceutical compositions may be administered or coadministered by various methods known in the art for administering biologically active agents to the bloodstream.
- the compositions may be administered by injection.
- the compositions may be administered by infusion.
- the composition may advantageously comprise a buffered saline solution of the conjugate.
- compositions for o delivery of isolated conjugated complexes comprising biologically active agents, particularly therapeutic agents such as anti-viral agents, where the complexes comprising the agents have an extended half-life in the bloodstream as compared to non-conjugated agents.
- the invention comprises using a biologically active compound covalently 5 attached or linked to a linking group, the linking group comprising at least one chemically reactive moiety which is capable of forming covalent bonds with functionalities present on the protein.
- the present invention provides for resistance-repellent, long- lasting and broad spectrum durable inhibitors of HTV gp41 and HTV, their compositions, methods of design, and uses thereof for treating drug-resistant HTV 5 and wtHJV infections in both salvage therapy and first-line therapy modalities.
- the invention provides resistance-repellent inhibitors of HTV gp41 that target wild type and drug-resistant mutant gp41 proteins, and that have antiviral activity against wild type and drug-resistant HTV strains.
- these compounds are active against wild type HTV strains that contain naturally- o occurring polymo ⁇ hisms in the sequence of gp41 , and that contain mutations that confer resistance to T-20 and/or T-1249.
- these inhibitors are peptide sequences that are related to peptide sequences of the N and C-terminal helical repeat regions of gp41.
- this invention relates to the design of broad spectrum durable (persistent) inhibitors of HTV gp41 that target wild type and drug- 5 resistant mutant gp41 proteins, and that have antiviral activity against wild type and drug-resistant HTV strains.
- these compounds are active against wild type HTV strains that contain naturally-occurring polymo ⁇ hisms in the sequence of gp41, and that contain mutations that confer resistance to T-20 and/or T-1249.
- the design of broad spectrum durable inhibitors of HTV gp41 relates to chemically o reactive modifications of peptides exhibiting anti-viral and/or anti-fusiogenic activity such that the modified peptides can react with available functionalities on blood components to form stable covalent bonds.
- the modified peptides comprise a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable 5 covalent bonds.
- the reactive group can be a moiety, such as a maleimide, which is reactive with a thiol group on a blood protein, including a mobile blood protein such as albumin.
- the present invention provides broad spectrum durable gp41 inhibitors which are capable of reacting with thiol groups on a blood o component, either in vivo or ex vivo, to form a stable covalent bond.
- the complexes formed from the methods disclosed herein are in themselves more stable and are longer acting than the un-modified compounds. These complexes formed from the present invention have an extended in vivo half-life when compared with the corresponding un-modified compounds.
- the complexes of the invention is 5 stable toward hydrolytic cleavage or degradation for a period of about 4 hours to about 120 days.
- this invention relates to the design of bioconjugated compositions of broad spectrum durable inhibitors of HTV gp41 that are covalently linked to a mobile blood protein such as serum albumin in a manner o such that the bioconjugated form of the inhibitor has antiviral activity against both wild type and drug-resistant HTV strains.
- these compounds are active against wild type HTV strains that contain naturally-occurring polymo ⁇ hisms in the sequence of gp41, and that contain mutations that confer resistance to T-20 and/or T-1249.
- the bioconjugates are formed using modified peptides that comprise a reactive group which is reactive with amino 5 groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.
- the reactive group can be a moiety, such as a maleimide, which is reactive with a thiol group on a blood protein, including a mobile blood protein such as albumin.
- the invention also provides the compounds described above bound in a 0 complex with wild type or drug resistant mutant forms of HTV-1 gp41.
- the invention further provides pharmaceutical compositions, comprising an inhibitor as described above, together with a pharmaceutically acceptable additive, excipient, or diluent.
- the composition may further comprise an additional HTV gp41 inliibitor and/or an HTV protease inhibitor and/or an HTV reverse transcriptase 5 inhibitor.
- the invention further provides methods of treating a patient suffering from HTV infection, comprising administering to the patient a pharmaceutical composition as described above.
- the present invention relates to biologically active o compounds that may be used to react with proteins to form covalently linked complexes wherein the resulting complexes are found to exhibit renin inhibition activities in vivo.
- the complexes are isolated complexes comprising a renin inhibitor and a linking group, and the blood component is a protein such as albumin.
- the present invention also provides methods for inhibiting 5 renin activity in vivo comprising administering to the bloodstream of a mammalian host the novel isolated complexes of the present invention.
- a pharmaceutical composition is provided that comprises a purified renin inhibitor complex according to the present invention as an active ingredient.
- compositions according to the invention may o optionally comprise 0.001 %- 100% of one or more renin inhibitors complexes of this invention.
- These pharmaceutical compositions may be administered or coadministered by various methods known in the art for administering biologically active agents to the bloodstream.
- the compositions may be administered by injection.
- the compositions may be administered by infusion. 5
- methods and compositions are provided for delivery of isolated conjugated complexes comprising biologically active agents, particularly therapeutic agents such as renin inhibitors, where the complexes comprising the agents have an extended half-life in the bloodstream as compared to non-conjugated agents.
- the invention comprises using a biologically active compound covalently attached or linked to a linking group, the linking group comprising at least one chemically reactive moiety which is capable of forming covalent bonds with functionalities present on the protein.
- a “complex” as used herein is a compound comprising a biologically active agent such as an anti-viral compound or a renin inhibitor, a linking group and a protein such as albumin.
- “Derivative” means a compound that is derived from some other compound 5 and usually maintains its general structure.
- isolated such as an isolated compound is a compound, such as a naturally occurring compound such as albumin, that is substantially separated from other components which accompany the compound in its natural state.
- isolated as applied to a compound obtained from blood or blood plasma, means a compound, o such as a particular biological component from blood protein or blood plasma, that is purified or isolated from other biological compounds or components in the blood or blood plasma before the compound is further conjugated with a biologically active agent such as an anti-viral agent or renin inhibitor or the like.
- the isolated compound exists in a physical milieu distinct from that in which it occurs in nature and/or has been completely or partially separated or purified from other components 5 in nature prior to submitting the compound to a reaction with the biologically active agent.
- the isolated compounds or complex of the invention has the advantage of allowing more selective reaction or conjugation with the biologically active agents, such as an anti-viral agent or renin inhibitor or the like, of the present invention with minimum interference from reactions with undesired components of the blood or 0 blood plasma.
- biologically active agents such as an anti-viral agent or renin inhibitor or the like
- Linker refers to a linking group which links or attaches a biologically active compound AV with a protein Pr, such as albumin, to form a covalently bound complex comprising the biologically active compound, the linker, and the protein.
- a protein Pr such as albumin
- “Pharmaceutically acceptable salts” means salts of inhibitors of the present o invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
- Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, 5 glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulf
- Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
- Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
- Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
- Protected derivatives means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors o anti-viral agents or in themselves maybe active as o inhibitors or anti-viral agents. A comprehensive list of suitable protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
- “Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment 5 for the disease.
- Treatment or “treating” means any administration of a compound of the present invention and includes:
- “Stable” a conjugate is stable when it is not cleaved prior to binding to a target, and where the macromolecular component of the conjugate, such as albumin, is not substantially degraded prior to target binding.
- the macromolecule is not o substantially degraded when, even though some protease cleavage may occur, the conjugate retains a molecular weight greater than about 50 kDa.
- the conjugate is considered intact when it retains a molecular weight of at least about 50 kDa.
- “Substantially retains” a conjugate substantially retains the activity of the pharmacologically active moiety when its activity is at least about 10% of the non- 5 conjugated pharmacologically active moiety (and may be higher on a molar ratio). Typically the activity of the conjugate is 0.1 to 10 times the activity of the non- conjugated pharmacologically active, though further enhancements of activity may be observed.
- “Pharmacologically inert” with respect to a macromolecule used in a o conjugate means that the molecule is non-toxic. The molecule may or may not have biological activity distinct from that of conjugate, thought it typically does not. "No biological activity” means that administration of non-conjugated carrier to subject does not produce any substantial perturbation in normal physiology of the subject. "Pseudo-peptides” or “peptide mimetics” or “peptidomimetics” means 5 modified peptides that are structural analogues of the peptide that are designed to mimic the structure, properties and activities of the peptide.
- the modified peptides have improved biological and functional activities compared to the un-modified peptide due to their higher level of resistance to enzymatic degradation while exhibiting the same or improved biological activities. o
- the peptide sequence will be understood to indicate N- protected derivatives such as N-acetyl compounds, and C-amide derivatives, as well as the free amino and free carboxy compounds.
- Figure 1 shows fusion inhibitor peptides of the invention.
- Figure 2 shows the pharmacokinetics of unconjugated (SPI-30014Q) vs HSA-conjugated (SPI30014HSA) fusion inhibitor peptide in Sprague-Dawley rats.
- Figure 3 shows the pharmacokinetics of unconjugated (SPI-70038Q) vs HSA-conjugated HTV (SPI-70038HSA) fusion inhibitor peptide in Sprague-Dawley o rats.
- Figure 4 shows the pharmacokinetics of Reactive peptide (SPI-30014) vs HSA- peptide conjugates (SPI-30014HSA) in Sprague-Dawley rats.
- Figure 5 shows the pharmacokinetics of reactive peptide (SPI-70038) vs HSA peptide conjugate (SPI-70038HSA) in Sprague-Dawley rats
- the invention provides conjugates, including purified conjugates, of a biologically or pharmacologically active moiety and a macromolecule, that have superior pharmacological properties and that produce sustained biological activity o when administered to a mammalian subject.
- the invention provides an isolated compound where a pharmacologically active moiety is covalently conjugated to a pharmacologically inert macromolecular carrier, where the linkage between the pharmacologically active moiety and the carrier is stable in vivo, where the intact compound substantially retains the pharmacological activity of the 5 pha ⁇ nacologically active moiety, and where the active half-life of the compound when administered to a mammal is at least about twice that of the unconjugated pharmacologically active moiety.
- the carrier advantageously is HSA and the conjugates are used for methods of human therapy and prophylaxis.
- conjugates that contain biologically active o molecules linked to macromolecular moieties.
- a significant body of work describes, for example, conjugates of the cytotoxic agents doxorubicin and methotrexate to human serum albumin (HSA) .
- HSA human serum albumin
- the rationale has been to link the cytotoxic agent to the HSA via a labile linkage that is severed upon uptake of the conjugate at the desired site in vivo.
- the labile linkage 5 is acid sensitive and is severed upon cellular uptake into the acidic environment of the endosome. In this manner, therefore, the conjugate was viewed in essence as a prodrug moiety that was required to be degraded to release the biologically active molecule.
- the non-covalent binding or adso ⁇ tion of a drug to a blood protein component is viewed as a disadvantage to the extent that protein binding 5 reduces the concentration of free drug available for pharmacological activity.
- the present inventors have found that ex vivo conjugation of a biologically active moiety to a macromolecule such as HSA produces a highly soluble conjugate that can be purified and administered in tightly controlled dosage.
- the cloaked conjugate is biologically active as the conjugate, i.e. it does not act as a prodrug that releases the biologically active moiety from the conjugate and cleavage o of the conjugate is not required for biological activity.
- the conjugate once administered to a subject the conjugate has a su ⁇ risingly long in vivo half-life, has excellent tissue distribution and produces sustained activity corresponding to the activity of the biologically active moiety of the conjugate.
- assays using radiolabeled conjugate show that essentially all of the administered conjugate can be accounted for in vivo following administration to the subject, In comparison, in 5 assays using radiolabeled active moiety, where the conjugate presumably is formed in situ, up to 50% of the active moiety administered to the subject cannot be accounted for.
- chemical conjugation between the biologically active moiety and the macromolecule permits variation in the length and nature of the linker. o
- the biologically active moiety and the macromolecule are linked in an approximately 1 : 1 ratio, to avoid "haptenization" of the biologically active moiety and generation of an immune response to the conjugate.
- the biologically active moiety is advantageously appended to a single site in the macromolecule.
- selective linkage to the unusually reactive cysteine 34 5 (C34) of HSA may be used.
- Methods for selective linkage to C34 using, for example, a maleimide containing linker, are known in the art. Suitable linkers are commercially available from, for example, Pierce (Rockford, TL).
- a linker can be appended to C34 of HSA that permits attachment of a plurality of biologically active moieties to the linker.
- Multivalent linkers are known in the art and can contain, for example, a thiophilic group for reaction with C34 of HSA, and multiple nucleophilic (such as NH or OH) or electrophilic (such as activated ester) 5 groups that permit attachment of a plurality of biologically active moieties to the linker.
- the biologically active moiety is relatively small in size compared to the macromolecule to maximize the "cloaking" effect of the macromolecule, such as HSA.
- the skilled artisan will recognize that o precise upper limits cannot be placed on the size of the biologically active moiety, it is believed that molecules with molecular weights less than 50 kD, less than 10 kD, and advantageously less than 7.5 kD or 5 kD can be used.
- the present mvention encompasses a wide variety of biologically and/or pharmacologically active moieties that may be "cloaked” using the methods described herein.
- pharmacologically active moieties that may be "cloaked” using the methods described herein.
- renin inhibitors and viral fusion inhibitors exemplified below, essentially any molecule for which enhanced pharmocological o properties, and in particular, sustained activity, are desirable, can be cloaked.
- Examples of groups that can be cloaked include peptide and non-peptide molecules. Specific examples include compounds having metabolic effects, such as cholesterol lowering and blood-pressure lowering compounds, compounds for treatment of neurological disorders (where the conjugate can be optionally administered directly 5 into the CNS) including wound healing agents, antibiotics (incuding anti-infectives), anti-oxidants, chemotherapeutic agents, anti-cancer agents, anti-inflammatory agents, and antiproliferative drugs. Examples of these molecules are well known in the art and include, merely for illustrative pu ⁇ oses:
- MMPs matrix metalloproteinases
- antagonists of the o urokinase receptor inhibitors of urokinase, erb-2 receptor antagonists, TRAIL receptor antagonists, antiangiogenic peptides, opiods and anti-nociceptive analogs for pain, antihypertensives such as renin inhibitors; angiotensm receptor antagonists; natriuretic peptide derivatives, antivirals such as interferons (including alpha and beta interferon for treatment of hepatitis C); cyanovirin derivatives, compounds for treatment of metabolic disorders such as insulin, bacterial and yeast extracellular 5 virulence factors such as proteinases, bacteriophage lysins, viral entry and fusion inhibitors (for viruses such as he ⁇ es viruses, such as HSV-2-genital he ⁇ es, viral glycoprotein D-nectin-2 interaction, HCV - E1,E2 glycoprotein interaction with CD81, LDL receptor and
- ACE-inhibitors - and ⁇ - adrenergic agonists agonists and antagonists, adrenocorticoids, hormones, aldose reductase inhibitors, aldosterone antagonists, 5- 5 reductase inhibitors, analgesics, anesthetics, anorexics, anthelmintics, antiacne agents, antiallergic agents, antialopecia agents, antiamebic agents, antiandrogen agents, antianginal agents, antiarrhythmic agents, antiarteriosclerotic agents, antiarthritic/antirheumatic agents, antiasthmatic agents, antibacterial agents, aminoglycoside antibiotics, ansamycins, antibiotics and antobacterials such as ⁇ - o lactams, lincosamides, macrolides, polypeptides, tetracyclines, 2,4- diaminopyrimidines, nitrofurans, quinolones and analogs, sulfonamide
- the present invention also provides anti-viral compounds that have prolonged or sustained activity for the treatment of viral disease.
- the invention also provides methods of treating viral diseases using these compounds.
- the compounds of the present invention have increased stability in vivo and a reduced susceptibility to degradation, for example by peptidase or protease degradation. As a result, the compounds of the present invention may be administered less frequently than presently available anti-viral compounds.
- the compounds can be used, e.g., as a prophylactic against and/or treatment for infection of a number of viruses, including human immunodeficiency virus (HTV), human respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV) and simian 5 immunodeficiency virus (STV).
- viruses including human immunodeficiency virus (HTV), human respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV) and simian 5 immunodeficiency virus (STV).
- the compounds of the invention achieve their sustained activity by covalent linkage to at least one blood component, or to a variety of different blood components.
- This linkage can be carried out in vivo or in vitro.
- the compound may optionally be further purified, by filtration 0 for example, prior to administration to a patient.
- the covalent linkage can be achieved either by chemical means, for example by using a suitable cross-linking agent, or by preparation of a fusion protein with the blood component.
- the 5 linkage may be achieved by chemical means. The skilled artisan will be aware of blood components that are suitable for use in the present invention.
- the blood component is human serum albumin, and in another embodiment the blood component is a human or humanized antibody, antibody fragment or antibody derivative.
- the antibody, antibody fragment or antibody o derivative may optionally be an antibody, antibody fragment or antibody derivative that specifically binds a blood component, such as human serum albumin.
- the compounds of the present invention include compounds having antiviral activity that can be conjugated to a blood component without a significant loss 5 of anti-viral activity.
- a significant loss of anti-viral activity refers to the situation where the anti-viral activity of the conjugated compound is reduced to the extent that the dosage of the compound must be increased by at least a factor of 10 in molar terms in order to obtain suitable in vivo activity.
- Compounds suitable for use in the present invention include, but are not limited to: peptide inhibitors of viral fusion, nucleoside and nucleoside analog, non- nucleoside and non-nucleoside analog and nucleotide and nucleotide analog inhibitors of viral enzymes, inhibitors of viral proteases, and chemokine co-receptor blockers that inhibit viral entry into cells. Examples of each of these compounds are known in the art.
- Non-limiting representative compounds include, for example: nucleoside analogs, such cytosine-arabinoside, adenine-arabinoside, iodoxyuridine and acyclovir: nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), such as AZT, ddl, ddC, d4T, 3TC, abacavir, tenofovir, emtricitabine, amdoxovir, dOTC, 0 and d4TMP; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine, delaviridine, efavirenz; thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, and TMC 125/R165335; protease inhibitors (Pis), which include saquinavir, ritonavir, indinavir, 5 nelfinavir
- antiviral compounds that can be used include lamivudine, famciclovir, lobucavir and adefovir, Ribavirin, integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), viral uncoating inhibitors (pleconaril); RNA replicase inhibitors (VP-32947); DNA polymerase inhibitors (A-5021, L- and D- 5 cyclohexenylguanine); bicyclic furopyrimidine analogues; cidofovir; neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201); adefovir dipivoxil; N- glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors.
- compounds can be used that o inhibit: viral adso ⁇ tion, through binding to the viral envelope glycoprotein gpl20 (polysulfates, polysulfonates, polycarboxylates, polyoxometalates, polynucleotides, and negatively charged albumins); viral entry, through blockade of the viral coreceptors CXCR4 (i.e., bicyclam 5 (AMD3100) derivatives) and CCR5 (i.e., TAK-779 derivatives); virus-cell fusion, through binding to the viral envelope glycoprotein gp41 (T-20, T-1249); viral assembly and disassembly, through NCp7 zinc finger-targeted agents (2,2'-dithiobisbenzamides (DTBAs), azadicarbonamide (ADA)); o proviral DNA integration, through integrase inhibitors such as 4-aryl-2,4- dioxobutanoic acid derivatives; and viral mRNA transcription,
- the Linkers LI and L2 5 A variety of different linkers or linking groups LI and L2 may be used to link the blood component with the anti-viral agent.
- the linking groups may be divalent or polyvalent.
- LI may be n- valent where it is attached to Pr, and m-valent where it attaches to AV where m and n are integers as defined above.
- L2 o may be o-valent where it is attached to Pr and p-valent where it is attached to AV, where o and p are as defined above.
- Non-exclusive examples of functional groups that may be present in a linking group include compounds that have a hydroxyl groups, such as N-hydroxysuccinimide, N-hydroxysulfosuccinimide, and other compounds such as maleimide-benzoyl-succinimide, 7-maleimido-butyryloxy 5 succinimide ester, maleimidopropionic acid, N-hydroxysuccinimide, isocyanate, thioester, thionocarboxylic acid ester, imino ester, carbodiimide, anhydride, or ester.
- a hydroxyl groups such as N-hydroxysuccinimide, N-hydroxysulfosuccinimide, and other compounds such as maleimide-benzoyl-succinimide, 7-maleimido-butyryloxy 5 succinimide ester, maleimidopropionic acid, N-hydroxysuccinimide, isocyanate, thioester, thion
- linking groups having functional groups such as carboxylate, acid halide, azido, diazo, carbodiimide, anhydride, hydrazine, 0 aldehydes, thiols, or amino group may be used to fonn amides, esters, imines, thioethers, disulf ⁇ des, substituted amines, or the like.
- acyloxymethylketones examples include acyloxymethylketones, aziridines, diazomethyl ketones, epoxides, iodo-, bromo- or chloroacetamides, ⁇ -haloesters, ⁇ -haloketones, sulfoniums, chloroethylsulfides, O-alkylisoureas, alkyl halides, vinylsulfones, acrylamides, vinylpyridines, organometallic compounds, 5 aryldisulfides, thiosulfonates, aldehydes, nitriles, ⁇ -diketones, ⁇ -ketoamides, - ketoesters, diaminoketones, semicarbazones, and dihydrazides.
- linker The nature and type of compounds that may be selected as the linker depends on the type of reactions, the relative reactivities, selectivities, reversibility and stability characteristics that are desired among the anti-viral agents, the linker 0 and the functional groups on albumin or the blood component.
- certain reactions that form the conjugate complex arise from an alkylation reaction, a Michael type reaction, an addition-elimination reaction, an addition to sulfur, carbonyl, or cyano groups, or the formation of a metal bond.
- the covalent bond that is formed from these reactions are stable 5 during the active lifetime of the anti-viral agent.
- the covalent bond that is formed in these complexes remain stable unless the biologically active subunit is intended to be released at the active site.
- the linkers may comprise of compounds having bifunctional or polyfunctional groups that are available for linking a protein such as albumin to o multiple anti-viral agents or for linking multiple albumins to a single anti-viral agent.
- the linker comprises polyfunctional groups that link a HSA to one or more anti-viral agents.
- linking compounds as used herein include any compounds that can link the antiviral agent to the protein in a single step.
- the linking 5 compounds are linked to the anti-viral agent first to form a inhibitor-linker intermediate that can be further reacted with the protein.
- the linking compounds are reacted with the protein first to form a protein-linker intermediate that can be further reacted with the anti-viral agent.
- the linked compounds may be further purified o and/or isolated before submitting to further reactions to form the complex of
- Non-exclusive examples of such polyfunctional compounds include compounds having at least one functional group selected from the group consisting of azidobenzoyl hydrazide, N-[4-(p-azidosalicylamino)butyl]-3'-[2'- pyridyldithio)propionamide), bis-sulfosuccinimidyl suberate, dimethyl 5 adipimidate, disuccinimidyl tartrate, N-y-maleimidobutyryloxysuccinimide ester, N-hydroxy sulfosuccinimidyl-4-azidobenzoate, N-succinimidyl [4-azidophenyl]- 1, 3 -dithiopropionate, N-succinimidyl [4-iodoacetyl]aminobenzoate, glutaraldehyde, and succinimidyl 4-[N-maleimidomethyl]cyclohe
- linker or linking group that is convenient for use and subject to standard chemical transformations, or linkers that form compounds that are physiologically acceptable at the desired dosages, and are stable in the bloodstream for the desired period of time, may be employed.
- the linking group may be aliphatic, alicyclic, aromatic, heterocyclic, or combinations thereof.
- groups that may be employed as a linking group include alkylenes, arylenes, aralkylenes, cycloalkylenes, polyethers and the like.
- polyfunctional polyethylene glycol (PEG) and their derivatives may also be employed as linkers.
- the linking groups may have at least one atom in the linking chain, more o preferably between 1 and 200 atoms in the chain, most preferably between 2 and
- the atoms in the chain can be linear or the chain can be part of one or more rings, each substituted or unsubstituted, and the chain may include carbons or heteroatoms selected from the group consisting of O N, P and S.
- the rings may be aliphatic, heterocylic, aromatic or heteroaromatic or mixtures 5 thereof, each substituted or unsubstituted.
- amino acids or peptides or amino acids employed with mixtures of the above may be used as a linking group.
- LI is absent and AV is attached directly to Pr.
- L2 is absent and AV is attached directly to Pr.
- LI is a linking group that is capable of linking more than one AV to one Pr, for example, where m is 2 or more. In one embodiment, m is 1, 2 or 3 and n is 1-30.
- Pr is albumin and n is 1. In another particular embodiment, Pr is albumin, AV is an anti-viral agent, and n is 2 - 25.
- L2 is a linking group that is capable of linking more than one Pr to one AV, for example, in the case where o is 2 or more, hi one embodiment, Pr is albumin, AV is an anti-viral agent, o is 1, 2 or 3 and p is 1-5.
- the linking group may be absent in cases where the inhibitor, such as an anti-viral agent, can be reacted directly with a protein, optionally using a catalyst or coupling agent, such that the complex that is fonned comprises only of the anti-viral agent that is directly attached to the protein.
- a direct coupling reaction is a mixed anhydride activated coupling reaction of a carboxylic acid followed by the coupling reaction of the intermediate mixed anhydride.
- Naturally occurring blood components include blood proteins, which include red blood cells, and immunoglobulins, such as IgM and IgG, seram albumin, transferrin, p90 and p38.
- the blood component or blood protein is albumin. More preferably, the albumin is a protein human serum albumin (HSA).
- the albumin used in the present invention may also be recombinant albumin.
- the recombinant human albumin may be produced by transforming a microorganism with a nucleotide coding sequence encoding the amino acid sequence of human serum albumin.
- Albumin is the main protein present in blood plasma, and may be extracted from blood, for examples as disclosed in JP 03/258 728, EP 428 758, EP 452 753, and 6,638,740 and references cited therein.
- Further examples of non-exclusive methods for the isolation of various compounds maybe based on selective reversible precipitation, ion exchange chromatography, protein affinity chromatography, hydrophobic chromatography, thiophilic chromatography (J. Porath et al; FEBS Letters, vol. 185, p.306, 1985; K. L.
- the linked compounds AV-L1 or AV-L2 of the present invention may be prepared and used in the conjugation with albumin without further purification and/or isolation.
- the purity of the linked compounds will depend on the nature of the linker, the nature of AV, and the type of reaction and reaction conditions employed to attach AV to the linker.
- the unpurif ⁇ ed linked compounds are prepared and obtained with a purity of at least 90%, preferably at least 95%, more preferably at least 97%, and most preferably at least 98%.
- the present invention relates to methods for the preparation of the isolated linked compounds, that is, AV-L1 or AV-L2.
- the isolated linked compounds AV-L1 and AVL2 are antiviral agents that are attached to a linker.
- the isolated linked compounds may be purified before conjugating with Pr.
- the linked compounds AV-L1 or AV-L2 are isolated and purified to a purity of at least 95%, preferably at least 97%, more preferably at least 98%, and most preferably at least 99% or more.
- the linked compounds may be prepared using standard methods known in the art of chemical synthesis.
- the compounds may be purified using standard methods known in the art, such as by column chromatography or HPLC to provide purified products suitable for in vivo applications.
- the linked compounds may be further conjugated with a protein, such as albumin to form the complex of Formulae I and II. Covalent linkage to blood components
- HSA Human serum albumin
- Activated linkers that are particularly suited for linkage to thiols include unsaturated cyclic imides such as maleimides, ⁇ -halo esters, such as c-iodo- and ⁇ -bromo acetates, and vinyl pyridine derivative.
- Suitable activated linkers are commercially available from, for example, 0 Pierce Chemical (Rockford, TL). Methods for preparing suitable activated compounds for linking to HSA are known in art. See for example, U.S. Patent No. 5,612,034, which is inco ⁇ orated herein in its entirety.
- the linker is specifically linked to the thiol group of cysteine 34, and maybe formed via a nucleophilic reaction of the s thiol group on an electrophilic group of the linker.
- fusion proteins which have therapeutic applications, include, but are not limited to a polypeptide, an antibody, or a peptide, or fragments and variants thereof, fused to a blood component.
- the o fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity.
- Methods of making fusion proteins are known in the art. See, for example, WO01/79271 and WO01/79258, the contents of which are hereby inco ⁇ orated by reference in their entirety.
- the preparation of fusion proteins is useful for preparing persistent derivatives of anti-viral peptides.
- Ig immunoglobulin
- Igs are persistent and are present in relatively high concentration in the blood.
- Igs have the advantage of being readily stable and readily isolated, and methods of making Ig conjugates are well known in the art.
- Ig genes may readily be cloned and o recombinant Ig and Ig fusion proteins prepared. Methods for obtaining fully human
- Igs are well known in the art. See for example, U.S. Patent Nos. 5,969,108 and 6,300,064, the contents of which are hereby inco ⁇ orated by reference in their entirety.
- phage display methods for selecting Igs having a particularly desired binding activity are well known in the art. See U.S. Patent Nos. 5,885,793, 5,969,108 and 6,300,064.
- an Ig refers to any suitable immunoglobulin or immunogolobulin derivative known in the art, and includes, for example, whole IgG, IgM, Fab fragments, F(ab')2 fragments, and single chain Fv fragments.
- blood components suitable for use in the present invention include transferrin, ferritin, steroid binding proteins, thyroxin binding protein, and ⁇ -2- 0 macroglobulin.
- activated linkers may be coupled to reactive side chain residues, such as lysine side chains.
- a linker containing an active ester moiety and a maleimide moiety can be selectively reacted at the active ester (such as an N-hydroxysuccinimidyl ester) via lysine side chains or at the N-terminus of the 5 peptide.
- the skilled chemist readily can recognize nucleophilic (or electrophilic) atoms or groups on the compound that can selectively react with a suitable linking moiety, such as an active ester. Suitable nucleophilic moieties include, but are not limited to, amino and hydroxyl groups.
- hydroxyl groups can act as o nucleophiles for the coupling reaction.
- coupling also can be achieved by formation of, for example, phospho esters.
- Similar strategies can be used in other anti-viral compounds, for example in protease inliibitors and other enzyme inhibitors, coupling can be achieved using nucleophilic groups that are distal from the enzyme active site. 5
- HSA and human Igs are commercially available and are suitable for use in the present invention.
- the antiviral compounds can be prepared using synthetic methods that are well known to the skilled chemist.
- peptides can be prepared using well-known techniques of solid-phase peptide synthesis. See, for example, Solid o Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Company, Rockford, JL, (1984).
- peptides fragments may be synthesized and subsequently combined or linked together to form the desired sequence.
- the compounds as represented by Pr may be albumin, may be used as obtamed from commercial sources without further purification or isolation, to prepare the linked compounds Pr-Ll and Pr-L2.
- Pr is HSA.
- the albumin may be further purified using various methods known in the art as disclosed herein.
- the linked compounds Pr-Ll and Pr-L2 may be prepared by treating a linker LI or L2, which may be derivatized or activated, with Pr, in a solution and monitoring the reaction mixture until the reaction is s substantially complete.
- Pr is a protein.
- the protein is HSA or recombinant HSA.
- the linked compounds Pr-Ll or Pr-L2 obtained are substantially pure; that is, the linked compounds are obtained with a purity of at least 10%, preferably at least 30%, and more preferably at least 50%.
- the Pr is HSA or recombinant HSA
- components that may be present with the linked compounds may comprise of unreacted HSA and various biological components that are present in the HSA starting material.
- the HSA or recombinant HSA is at least 10% pure on a dry matter basis.
- HSA or HSA related biologically materials present with the 5 linked compounds will not significantly interfere with the subsequent conjugation step with AV.
- the related biological materials and the conjugated complexes will also be pharmacologically safe for use in vivo.
- the purity of the linked compounds Pr-Ll or Pr-L2 may be at least 10% on a dry matter basis to enable the selective o reaction of the compounds with AV without a significant amount of interferences or without the formation of undesirable by-products obtained from the conjugate reaction with other undesired blood components.
- the desired purity of Pr such as HSA or recombinant HSA, for example, will depend on the nature of the functional groups on Th as well as the functional groups employed on the linker. Typically, higher purities of HSA or recombinant HSA is required if the 5 functional groups on the linker are more reactive and may form undesired byproducts than functional groups on the linker that are less reactive.
- the albumin may be obtained from plasma or blood albumin from a host, purified to a desired level of purity, and linked with the linker. Purification of the albumin from blood or blood plasma may be performed using well established l o standard methods known in the art for the purification of albumin. Using purified blood albumin, the isolated complexes of the present will comprise of a relatively homogeneous population of functionalized proteins.
- the complexes of Formula I or Formula II may be 15 prepared by the conjugation of AV-Ll or AV-L2 with Pr, the conjugation of Pr-Ll or Pr-L2 with AV, or the conjugation of AV with Pr to form a complex wherein the linker is absent.
- a solution of AV-Ll or AV-L2 is combined with Pr under conditions such that the conjugation reaction is deemed to be complete.
- the linked compound is an anti-viral agent that is attached to a linker, and the linked compound is added to an aqueous solution of HSA.
- the resulting solution is incubated until the reaction is substantially complete.
- the AV-Ll or AV-L2 is combined with an excess of
- the conjugate reaction of AV-Ll or AV-L2 with HSA occurs on a single cysteine of HSA.
- the conjugate reaction may 3 o also occur initially with a cysteine -SH group to form a kinetic product that is then rea ⁇ anged to another amino acid functional group, such as a lysine, to form the thermodynamic product.
- the conjugate reaction may form the complex of Formula I, for example, wherein more than one AV is linked to a single HSA to 5 form the complex of Formula I; that is, wherein n is greater than 1.
- m may be greater than 1 if the linker LI is a polyfunctional linker that is capable of attaching more than one AV group.
- the complex of Formula I may be prepared by combining an excess of Pr relative to (AV)m-Ll .
- the ratio of Pr to (AV)m-Ll is about 50 to 100.
- o the ratio is from about 10 to 30.
- the ratio is from about 2 to 5.
- Pr is added to (AV)m-Ll in a ratio of at least about 1.1:1, more preferably at least about 1.2:1, and most preferably at least about 1.4: 1.
- the preferred ratios are based on the 5 assumption that there is 0.7 free thiol per albumin.
- the resulting complex is formed as a 1 : 1 complex, since a Pr component such as albumin has only about 70% free thiol functionality for conjugation.
- An excess of Pr, such as HSA or recombinant HSA is pharmacologically safe and may not require further purification.
- the o conjugated complex may be purified to a purity of at least 10%. In a particular embodiment, the conjugated complex may be purified to at least about 20% or at least about 30%.
- the complex of Formula I may be prepared by combining an excess of (AV)m-Ll relative to Pr.
- the ratio of (AV)m- 5 LI to Pr is about 50 to 100.
- the ratio is from about 10 to 30.
- the ratio is from about 2 to 5.
- the conjugated complex may be purified to a purity of at least 10%.
- the conjugated complex may be purified to at least about 20% or at 0 least about 30%.
- the complexes of Formula I or Formula U may be prepared from a stoichiometric ratio of (AV)m-Ll with Pr or a stoichiometric ratio of AV with L2-(Pr)o, that is, in a 1 : 1 ratio.
- the resulting product from these preparations may be further purified to a purity of at least 10%.
- the conjugated complex may be purified to at least about 20% or to a purity of at least about 30%.
- the 1 : 1 conjugated complex may be further purified to a purity of greater than about 90%.
- the conjugated cysteine present in albumin is 0 reduced to the free cysteine prior to the reaction.
- the complex formed from the conjugate reaction may be further purified prior to administration.
- the complexes of Formula I or Formula TI obtained from the conjugate reaction may be administered without further processing or 5 purification since an excess of HSA or HSA related biologically materials present with the complexes are pharmacologically safe for use in vivo.
- AV is a peptide anti-viral agent and Pr is HSA or recombinant HSA.
- the isolated complex comprising a protected or o unprotected anti-viral agent with a linker and albumin may be optionally further purified and then returned to the host.
- the complexes formed from the methods of the present invention may be tested in animal or human hosts until the physiology, pharmacokinetics, and safety profiles are well established over an extended period of time.
- the 5 measured half-life of the complexes is about 5 to 7 days, more typically at least about 7 to 10 days, and preferably 15 to 20 days or more.
- the duration is species dependent.
- the half life is about 17- 19 days.
- the effective therapeutic concentration of the complexes o may be at least 1 month or more.
- Half lives may be determined by serial measurements of whole blood, plasma or serum levels of the complexes of Formula I or Formula ⁇ , the AV-L compounds, the L-Pr compounds, or the AV compounds following labeling of the complex or compounds with an isotope (e.g., 1311, 1251, Tc, Cr, 3H, etc ...) or 5 fluorochrome and injection of a known quantity of labeled complex or compound intravascularly. Included are red blood cells (half life ca. 60 days), platelets (half life ca.
- the subject components are preferably in cell count or concentration sufficient to allow binding of therapeutically useful amounts of the compound of the present invention.
- the desired half life for the effective therapeutic concentration of the complex and/or the biologically active agent may o vary from the measured half-life above.
- the rate of release of the biologically active agent depends in part, on the valency or the functionality on the biological agent which is to be released, the nature of the linking group, the purity and type of the protein, the composition for administration, the manner of administration, and the like.
- linking groups and biological agents may be 5 employed, where the environment of the blood, components of the blood, particularly enzymes, activity in the liver, or other agent may result in the cleavage of the linking group with release of the biological agent in the host at a desired rate.
- the isolated complexes of the present invention provides biological active o compounds that have improved pharmacokinetics, solubility, bioavailabihty, distribution, and/or immunogenicity characteristics as compared to the non- conjugated compounds.
- the complexes of Formula I and Formula ⁇ when prepared and used according to the methods of the present invention, provides an effective therapeutic concentration for a significantly longer time than the AV component by itself.
- the complexes of the present invention provide improved solubility, distribution, pharmacokinetics, and result in decrease immunogenicity when compared to the administration of the AV component by itself.
- the present inventors su ⁇ risingly have found that administration to a subject of a conjugate that is prepared ex vivo from purified components
- HSA HSA, linker and an anti-viral agent
- a therapeutically effective amount of a composition is understood to mean an amount that, when administered to a subject, produces a desired physiological effect to a degree that is effective for freatment of a disease, condition, or syndrome in the patient, or that is effective in alleviating the symptoms disease, condition, or syndrome.
- the genes encoding the fusion protein are placed into a suitable vector in frame, and the vector is used to transform a suitable host cell.
- the genes may be placed in either order (i.e. the anti-viral peptide may be placed at the N- or C- terminus of the fusion protein) and may be directly fused or separated by a linker peptide.
- Suitable linker peptides are known in the art and include peptide sequences that have little secondary structure of their own and that are hydrophilic, for example, linkers containing mixtures of glycine and serine residues. Methods for making fusion proteins of HSA are described in WO01/79271 and WO01/79258, and similar methods can be used for making fusion proteins with other blood 5 components.
- the present invention particularly contemplates use of peptides that inhibit viral fusion with the cell membrane, and in particular contemplates peptides that inhibit fusion of HTV.
- Specific peptide inhibitors typically contain up to about 51 amino acids, and contains a peptide having the sequences as discosed herein. In 0 particular, the peptides may contain the sequences shown in Figure 1. These sequences are derived from sequences found in HTV isolates and, for peptides longer than the sequences shown in Figure 1, for example, the remainder of the peptide sequence can be either N- or C- terminal to the sequence shown. Such additional sequences can, for example, consist of, or can contain, the sequences that occur 5 adjacent to the defined sequences in those HTV isolates.
- the administration of the isolated complex of the present invention may be accomplished using a bolus, but may be introduced slowly over time by transfusion using metered flow, or the like.
- the complex of the present invention may be administered in a physiologically acceptable medium, e.g. deionized water, phosphate buffered saline, saline, mannitol, aqueous glucose, alcohol, vegetable oil, or the like.
- a single injection may be employed although more than one injection may be used, if desired.
- the complex may be administered by any convenient means, including 5 syringe, trocar, catheter, or the like.
- the particular manner of administration will vary depending upon the amount to be administered, whether a single bolus or continuous administration, or the like.
- the administration may be intravascularly, where the site of introduction is not critical to this invention, preferably at a site where there is rapid blood flow, e.g. intravenously, peripheral or central vein. o Other routes may find use where the administration is coupled with slow release techniques or a protective matrix.
- the administration of the isolated complexes prepared by the methods of the present invention results in anti-viral conjugate complexes that maintain an effective therapeutic effect in the bloodstream for an extended period 5 of time as compared to a non-conjugated anti-viral agents or as compared to complexes that are not prepared from isolated blood protein such as albumin.
- the present invention provides the compounds in the form of a pharmaceutically acceptable salt.
- the present invention provides the compounds o present in a mixture of stereoisomers. In yet another embodiment, the present invention provides the compounds as a single stereoisomer.
- the present invention provides pharmaceutical compositions comprising the compound as an active ingredient.
- the present invention provides pharmaceutical composition 5 wherein the composition is a tablet or a solid for administration as a depot.
- the present invention provides the pharmaceutical composition wherein the composition is a liquid formulation adapted for TV or subcutaneous administration.
- the present invention provides pharmaceutical composition wherein the composition is a o liquid formulation adapted for parenteral administration.
- prodrugs themselves also fall within the scope of the range of compounds according to the present invention.
- prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 5 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like) or an acylating agent.
- carbamylating agent e.g., 5 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like
- an acylating agent e.g., 5 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like.
- Protected derivatives of compounds of the present invention can also be 0 made. Examples of techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
- Hydrates 5 of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxane, tettahydrofuran or methanol.
- a "pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the o form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound.
- the pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the 5 compound with respect to its therapeutic activity in the body.
- An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the abso ⁇ tion, distribution, biotransformation and excretion of the compound.
- the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which is utilized.
- an aqueous solution of the compound will provide the most rapid abso ⁇ tion of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid abso ⁇ tion of the compound.
- a peptide consisting of up to 51 amino acids comprising the sequence
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and H;
- Y6 is selected from the group consisting of any amino acid except P, G and
- each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7, wherein
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and H;
- Y6 is selected from the group consisting of any amino acid except P, G and C; 5 Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D; and each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence 0 Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8, wherein
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, 5 and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P; and each X independently is any amino acid. 5 hi another embodiment of the invention, there is provided a peptide consisting of up to 51 amino acids comprising the sequence
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, o and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and
- Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P;
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;
- each X independently is any amino acid.
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and
- Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R
- each X independently is any amino acid.
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and H;
- Y6 is selected from the group consisting of any amino acid except P, G and C;
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R
- Yl 1 is selected from the group consisting of N, S, T, V, A and D
- each X independently is any amino acid.
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and
- H; Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P;
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R;
- Yl 1 is selected from the group consisting of N, S, T, V, A and D; Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S; and each X independently is any amino acid.
- a peptide of up to 51 amino acids comprising the sequence Y1-X-X-Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-
- Yl is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and H;
- Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P;
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R;
- Yl 1 is selected from the group consisting of N, S, T, V, A and D
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;
- Y13 is selected from the group consisting of L, I, V, K and R; and each X independently is any amino acid.
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and
- Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P;
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R;
- Yl 1 is selected from the group consisting of N, S, T, V, A and D;
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;
- Y13 is selected from the group consisting of L, I, V, K and R;
- Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R; and each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence Y2-X-X-X-Y3-X-X-X-Y4-X-X-Y5-X-X-Y6-Y7-X-X-X-Y8-X-Y9-Y10-X- X-Y11-Y12-X-X-Y13-Y14, wherein:
- Y2 is selected from the group consisting of W, Y, F, H, L, N, Q, E, D, K, and R;
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and
- Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R
- Yl 1 is selected from the group consisting of N, S, T, V, A and D;
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;
- Y13 is selected from the group consisting of L, I, V, K and R;
- Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R; and each X independently is any amino acid.
- Y3 is selected from the group consisting of I, V, L, A, S and T;
- Y4 is selected from the group consisting of T, S, I, K, N, H, R, Q, E and D;
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and H;
- Y6 is selected from the group consisting of any amino acid except P, G and
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R, N, E, D, K and P;
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;
- Y13 is selected from the group consisting of L, I, V, K and R;
- Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R; and each X independently is any amino acid.
- Y6 is selected from the group consisting of any amino acid except P, G and C;
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R
- Yl 1 is selected from the group consisting of N, S, T, V, A and D;
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;
- Y13 is selected from the group consisting of L, I, V, K and R;
- Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R; and each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence
- Y5 is selected from the group consisting of I, V, T, K, L, N, Q, D, E, R and
- Y6 is selected from the group consisting of any amino acid except P, G and C;
- Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R, N, E, D, K and P;
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P;
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R;
- Yl 1 is selected from the group consisting of N, S, T, V, A and D;
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S;
- Y13 is selected from the group consisting of L, I, V, K and R; Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R; and each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence
- Y6-Y7-X-X-X-Y8-X-Y9-Y10-X-X-Y11-Y12-X-X-Y13-Y14 wherein: Y6 is selected from the group consisting of any amino acid except P, G and C; Y7 is selected from the group consisting of I, L, V, N, Q, K, R, H, E and D;
- Y8 is selected from the group consisting of Q, H, R,N, E, D, K and P
- Y9 is selected from the group consisting of Q, H, N, E, D, K, R, L and P
- Y10 is selected from the group consisting of Q, H, N, E, D, K and R
- Yl 1 is selected from the group consisting of N, S, T, V, A and D
- Y12 is selected from the group consisting of E, V, K, G, R, Q, D, N, H, T and S
- Y13 is selected from the group consisting of L, I, V, K and R;
- Y14 is selected from the group consisting of L, S, M, Y, N, Q, E, D, K, and R; and each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence
- each X independently is any amino acid.
- a peptide consisting of up to 51 amino acids comprising the sequence
- XI is selected from the group consisting of M, L, I, Q, T , R and K; X2 is either E, D, Q and K;
- X3 is selected from the group consisting of E, D and K;
- X4 is selected from the group consisting of K, R , E, Q, N and T;
- X5 is selected from the group consisting of E, L, R, K and Q;
- X6 is selected from the group consisting of N, D, S, E, Q, K, R, H, T, I and G;
- X7 is selected from the group consisting of N, Q, D, E, K, S, T and Y;
- X8 is selected from the group consisting of Y, F, H, I, V and S;
- X9 is selected from the group consisting of G, K, R, H, D, E, S, T, N and Q;
- XI 0 is selected from the group consisting of K, H , E, Q , T, V, I, L, M, A, Y, F, and P;
- XI I is selected from the group consisting of H, K, E, Y and F;
- XI 2 is selected from the group consisting of T, S, Q, N, E, D, R, K, H, W, G, A, and M;
- XI 3 is selected from the group consisting of D, E, Q, T , K, R, A, V and G;
- X14 is selected from the group consisting of D, E, K, H, Q, N, S, I, L, V, A and G;
- XI 5 is selected from the group consisting of S, A and (P);
- XI 6 is selected from the group consisting of N, K, S, T, D, E, Y, I and V;
- XI 7 is selected from the group consisting of E, D, N, K, G, and V;
- XI 8 is selected from the group consisting of K, R, H, D, E, N, Q, T, M, I, and Y;
- XI 9 is selected from the group consisting of E, V, Q, M , L, J, and G;
- X20 is selected from the group consisting of Q, N, E, K, R, H, L, and F;
- X21 is selected from the group consisting of E, D, N, S, K, A, and G;
- X22 is selected from the group consisting of L, I, and Y; and X23 is selected from the group consisting of I, L, M, Q, S, and Y.
- the peptide comprises a sequence selected from the group consisting of the sequences shown in Figure 1.
- AV is an antiviral compound
- LI and L2 are polyvalent linkers covalently linking AV to Pr, or where LI and L2 are absent; Pr is a protein; and wherein the complex possesses antiviral activity in vivo.
- the antiviral compound is a peptide.
- the peptide has a mass of less than about 100 kDA.
- the peptide has a mass of less than about 30 kDA.
- the peptide has a mass of less than about 10 kDA.
- the peptide is a peptidomimetic.
- the peptide consists of up to 51 5 amino acids comprising a sequence selected from the group consisting of:
- XI is selected from the group consisting of M, L, I, Q, T , R and K; X2 is either E, D, Q and K;
- X3 is selected from the group consisting of E, D and K;
- X4 is selected from the group consisting of K, R , E, Q, N and T;
- X5 is selected from the group consisting of E, L, R, K and Q;
- X6 is selected from the group consisting of N, D, S, E, Q, K, R, H, T, I and G;
- X7 is selected from the group consisting of N, Q, D, E, K, S, T and Y;
- X8 is selected from the group consisting of Y, F, H, I, V and S;
- X9 is selected from the group consisting of G, K, R, H, D, E, S, T, N and Q;
- XI 0 is selected from the group consisting of K, H , E, Q , T, V, I, L, M, A, Y, F, and P;
- XI I is selected from the group consisting of H, K, E, Y and F;
- X12 is selected from the group consisting of T, S, Q, N, E, D, R, K, H, W, G, A, and M;
- XI 3 is selected from the group consisting of D, E, Q, T , K, R, A, V and G;
- X14 is selected from the group consisting of D, E, K, H, Q, N, S, I, L, V, A and G;
- XI 5 is selected from the group consisting of S, A and (P);
- XI 6 is selected from the group consisting of N, K, S, T, D, E, Y, I and V;
- XI 7 is selected from the group consisting of E, D, N, K, G, and V;
- XI 8 is selected from the group consisting of K, R, H, D, E, N, Q, T, M, I, and Y;
- XI 9 is selected from the group consisting of E, V, Q, M , L, J, and G;
- X20 is selected from the group consisting of Q, N, E, K, R, H, L, and F;
- X21 is selected from the group consisting of E, D, N, S, K, A, and G;
- X22 is selected from the group consisting of L, I, and Y;
- X23 is selected from the group consisting of I, L, M, Q, S, and Y.
- the peptide sequence disclosed herein comprising the fragment of the peptide that consists of up to 51 amino acids may be a fragment of the 51 amino acid peptide that is located at the N-terminus, the C-terminus or anywhere in the interior of the 51 amino acid peptide.
- the peptides are the C-terminus 5 amides (-CONH 2 ) and their protected derivatives.
- the peptides are the C-terminus esters (i.e.-COOR, where R is substituted or unsubstituted (CM S )alkyls).
- the peptide sequence disclosed herein comprising the fragment may be further protected by standard protecting groups known in the art.
- Protected o derivatives of these peptides are useful in the preparation of the antiviral compounds or are useful in themselves as active antiviral compounds in their partially or fully protected forms. That is, the derivatized or protected or partially protected peptide fragments in the complex may still retain the ability to bind the target and manifest therapeutic biological activities.
- representative protecting groups for 5 amino groups of the peptide fragments include acetyl, fe/ -butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable and representative protecting groups can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, hie. 1999.
- the protecting group for the peptide fragments comprise o C-terminal amides and or N-terminal acetyl groups and their derivatives.
- the peptides may have any functional groups of the amino acids, including -NH, -SH, -OH, -COOH, and the like, that may be attached to the linker.
- the protein is a blood component.
- the blood component is selected from the group consisting of red blood cells, immunoglobulins, IgM, UiG, serum albumin, transferrin, P90 and P38, ferritin, a steroid binding protein, thyroxin binding protein, and ⁇ -2-macroglobulin.
- the blood component is human serum albumin and the linker is a peptide linker.
- the blood component is human seram albumin and the linker is a non-peptide linker.
- the complex is a fusion protein.
- the Tinier LI or L2 is a non-labile linker that is stable toward hydrolytic cleavage in vivo. Therefore, the complexes of the 5 present invention provides compounds that are stable toward hydrolytic cleavage in vivo, hi addition, the complexes of the present invention are also active compounds in themselves and are not simply a prodrug of the peptides that are generated or released upon hydrolysis in vivo.
- WO 00/76550 discloses pharmaceuticals and/or diagnostic active o substances attached to a spacer molecule that is attached to a thiol binding group, such as native or recombinant albumin.
- a spacer molecule that is attached to a thiol binding group, such as native or recombinant albumin.
- the disclosure teaches that the release of the pharmaceutical compounds or the diagnostic active substances is prefered since the low molecular weight active substance must interact with the target molecule to that it is pharmacologically active.
- Kratz teaches that 5 the spacer molecule are selected from compounds that are hydrolytically and/or pH- dependent and/or are ezymatically scissile. Preferably, these spacer molecules are acid sensitive or acid-unstable spacers.
- the linker LI or L2 can be a hydrophobic linker, a hydrophilic linker, or combinations thereof when more than one linker is present.
- the variety of different o linker LI or L2 can be selected to provide different solubility characteristics and cell penetrability chracteristics.
- the linker LI or L2 may be attached to the peptide at the N-terminus, the C-terminus, at a reactive side chain on an internal amino acid(s) 5 such as, for example, with a lysine, aspartic acid, glutamic acid, or cysteine, or combinations thereof.
- the linker LI or L2 comprises at least two functional groups covalently linking AV to Pr.
- the linker LI or L2 is hydrolytically stable in human serum for an extended period of time. 0 It was determined that the complexes of the present invention are compounds that are themselves more stable toward hydrolytic cleavage or degradation than the non-complexed compounds.
- the complex of the present invention are stable toward hydrolytic cleavage or degradation, having half lives in human serum for a period of 4 hours to 120 days. In a particular variation, the complex of the present invention are stable toward hydrolytic 5 cleavage or degradation for a period of about 8 hours to about 30 days.
- the linker LI or L2 is stable in human serum for half lives of 8 hours to 30 days.
- the linker LI or L2 is a derivative of a compound selected from the group consisting of acyloxymethylketones, aziridines, diazomethyl ketones, epoxides, iodo-, bromo- or chloroacetamides, ⁇ -haloesters, G!-haloketones, sulfoniums, chloroethylsulfides, O-alkylisoureas, alkyl halides, vinylsulfones, acrylamides, acrylates, vinylpyridines, organometallic compounds, aryldisulfides, 5 thiosulfonates, aldehydes, nitriles, ⁇ -diketones, ⁇ -ketoamides, ⁇ -ketoest
- the linker LI or L2 is a derivative of a compound selected from the group consisting of azidobenzoyl hydrazide, N-[4-(p-azidosalicylamino)butyl]-3'-(2'- o pyridyldithio)propionamide, bis-sulfosuccinimidyl suberate, dimethyl adipimidate, disuccinimidyl tartrate, N-y-maleimidobutyryloxysuccinimide ester, N-hydroxy sulfosuccinimidyl-4-azidobenzoate, N-succinimidyl [4-azidophenyTJ-l ,3'- dithiopropionate, N-succinimidyl [4-iodoacetyl]aminobenzoate, glutaraldehyde, succinimidyl 4-[N-maleimido
- a complex of the invention o wherein the protein is albumin.
- the albumin is HSA or recombinant HSA that is at least 10% pure on a dry matter basis.
- the linkage is to a Cys-34 of human albumin.
- the complex is prepared by combining a stoichiometric ratio of (AV) m -Ll with Pr or a stoichiometric ratio of AV with L2-(Pr) 0 .
- the ratio of (AV) m -Ll to Pr, or the ratio of AV to L2-(Pr) 0 are 1 : 1.
- the complex is prepared by combining a mixture of Pr to (AV) m -Ll in a ratio of at least about 1.3:1.
- LI and L2 are absent, and wherein the complex is prepared by forming an activated intermediate of AV followed by the condensation of the activated AV intermediate with Pr.
- the activated intermediate of AV is prepared from a mixed anhydride or N,N'-carbonyldiimidazole reagent.
- the complex is further purified to a purity of at least about 30%.
- the formation of the complex of the present invention result in a more soluble complex for formulation, which is a significant advantage for the administration (via injection) over the administration of the insoluble unconjugated drug.
- the present method allows the preparation of stable, physiological solutions.
- the ability to prepare stable, soluble solution compositions containing the complex of the present invention allows the preparation of physiological saline solution of the complex for ease of oral or parenteral administration.
- the formation of the complex ex vivo has been found to be 5 preferable over the in vivo formation of the complex because the administration of the complex results in less irritation at the injection site, avoids the non-specific reaction with other proteins, and achieves an improved therapeutic blood levels of the complex than the in vivo approach.
- the invention provides an anti-viral composition 0 comprising a non-peptidic anti-viral compound covalently linked to a blood component.
- compositions comprising the complex and a physiologically acceptable carrier.
- the composition is formulated with saline or fonnulated without saline.
- the composition is formulated for parenteral administration.
- Administration of the composition of the present invention may include parenteral administration, including by injection through other route such as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrastemal, o intracerebral ventricular (ICV), intravenous, and the like.
- parenteral administration including by injection through other route such as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrastemal, o intracerebral ventricular (ICV), intravenous, and the like.
- the composition is selected from the group consisting of solutions, dry products for combining with a solvent prior to use, suspensions, emulsions, and liquid concentrates.
- a method for 5 inhibiting the activity of HTV gp41 and HTV in vivo comprising: administering to the bloodstream of a mammalian host an isolated conjugate complex of the above embodiments and variations, wherein the complex is formed by attaching an antiviral compound to a linker having at least one reactive functional group which reacts with the protein to form stable covalent o bonds; and wherein the isolated conjugate complex is administered in an amount to maintain an effective therapeutic effect in the bloodstream for an extended period of time as compared to a non-conjugated antiviral compound.
- the method may be applicable to the 5 complexes disclosed in the above embodiments and variations.
- the method employs a protein wherein the protein is HSA or recombinant HSA.
- the linker comprising a reactive functional group is a compound selected from the group consisting of 0 acyloxymethylketones, aziridines, diazomethyl ketones, epoxides, iodo-, bromo- or chloroacetamides, ⁇ -haloesters, ⁇ -haloketones, sulfoniums, chloroethylsulfides, O-alkylisoureas, alkyl halides, vinylsulfones, acrylamides, acrylates, vinylpyridines, organometallic compounds, aryldisulfides, thiosulfonates, aldehydes, nitriles, ⁇ -diketones, ⁇ -
- a method for eliciting antiviral activity in vivo comprising: administering into the bloodstream of a mammalian host the complex of the above embodiments and variations in an amount sufficient to provide an o effective amount for antiviral activity; whereby said complex is maintained in the bloodstream over an extended period of time as compared to the lifetime of unbound antiviral compound.
- a method for eliciting antiviral activity in a host comprising: 5 a) preparing a compound AV-Ll or AV-L2 wherein AV is a peptide antiviral compound with a mass of less than 60 kD and LI or L2 is a linker covalently bound to AV; b) treating the compound AV-Ll or AV-L2 with isolated protein ex vivo for a time sufficient for the compound AV-Ll or AV-L2 to covalently bond to the o protein to form the protein complex of the above embodiments and variations, and c) administering the treated protein complex to the host.
- the protein is albumin.
- the albumin is HSA or recombinant HSA.
- the albumin is obtained from blood, purified and isolated from blood prior to treating the albumin with the compound AV-Ll or AV-L2.
- the albumin is purified to a purity level of at least 10% on a dry matter basis.
- the albumin is purified to a purity level of more than 95%.
- the invention provides a method for eliciting antiviral activity in a host, said method comprising: a) preparing a compound AV-Ll or AV-L2 wherein AV is an antiviral compound peptide with a mass of less than 60 kD and LI or L2 is a linker covalently bound to AV; b) treating the compound AV-Ll or AV-L2 with isolated one or more protein Pr ex vivo for a time sufficient for the compound AV-Ll or AV-L2 to covalently bond to one or more of the isolated proteins to form one or more modified protein complex of the above embodiments and variations; and c) administering the modified protein or proteins to the host.
- the protein is albumin.
- the albumin is obtained from blood, purified and isolated from blood prior to treating with the compound AV-Ll or AV-L2.
- the albumin is HSA or recombinant HSA.
- the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a complex of the above embodiments and variations, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.
- the invention provides a process for inhibiting the action of the HTV virus which process comprises administering to a host in recognized need of such treatment an effective amount of a complex of the above embodiments and variations, or a pharmaceutically acceptable salt thereof.
- the mvention provides a method of treating a subject suffering from a viral infection, comprising administering to said subject an effective amount of a composition of the above embodiments and variations. According to the above variations, the subject is suffering from HTV infection.
- the invention provides a method of prophylaxis in a patient suspected of being exposed to a viral infection, comprising administering to 5 said subj ect an effective amount of a composition of the above variations.
- the present invention takes advantage of the properties of existing anti-viral agents.
- the viruses that may be inhibited by the compounds of the present invention include, but are not limited to all strains of viruses listed, e.g., in US 6,013,263 and 0 US 6,017,536 at Tables V-VH and TX-XTV therein.
- viruses include, e.g., human retroviruses, including HTV-1, HTV-2, and human T-lymphocyte viruses (HTLV-I and HTLV-TT), and non-human retroviruses, including bovine leukosis virus, feline sarcoma virus, feline leukemia virus, simian immunodeficiency virus (STV), simian sarcoma virus, simian leukemia, and sheep progress pneumonia virus.
- human retroviruses including HTV-1, HTV-2, and human T-lymphocyte viruses (HTLV-I and HTLV-TT)
- non-human retroviruses including bovine leukosis virus, feline sarcoma virus, feline leukemia virus, simian immunodeficiency virus (STV), simian sarcoma virus, simian leukemia, and sheep progress pneumonia virus.
- Non-retroviral viruses may also be inhibited by the compounds of the invention, for example human respiratory syncytial vims (RSV), canine distemper virus, Newcastle Disease virus, human parainfluenza virus (HPJV), influenza viruses, measles viruses (MeV), Epstein-Ban viruses, hepatitis B viruses, and simian Mason-Pfizer viruses.
- RSV human respiratory syncytial vims
- canine distemper virus Newcastle Disease virus
- HPJV human parainfluenza virus
- influenza viruses measles viruses
- Epstein-Ban viruses Epstein-Ban viruses
- hepatitis B viruses hepatitis B viruses
- simian Mason-Pfizer viruses simian Mason-Pfizer viruses.
- Non-enveloped viruses may also be inhibited, and include, o but are not limited to, picornaviruses such as polio viruses, hepatitis A virus, enteroviruses, echoviruses, coxsackie viruses, papovaviruses such as papilloma virus, parvoviruses, adenoviruses, and reoviruses.
- picornaviruses such as polio viruses, hepatitis A virus, enteroviruses, echoviruses, coxsackie viruses, papovaviruses such as papilloma virus, parvoviruses, adenoviruses, and reoviruses.
- the compounds of the present invention may be administered to patients according to the methods described below and other methods known in the art. 5 Effective therapeutic dosages of the compounds derivatives may be determined tlirough procedures well known by those in the art.
- the compounds also can be administered prophylactically to previously uninfected individuals. This can be advantageous in cases where an individual has been exposed to a virus, as can occur when individual has been in contact with an o infected individual where there is a high risk of viral transmission. This can be especially advantageous where there is no known cure for the virus, such as the HTV virus.
- prophylactic administration of a compound of the invention would be advantageous in a situation where a health care worker has been exposed to blood from an HTV-infected individual, or in other situations where an individual engaged in high-risk activities that potentially expose that individual to the HTV 5 virus.
- the prefened route of administration of the compounds of the invention is via intravenous administration, which allows the compounds to circulate in the bloodstream and reach their desired target.
- the methods of the present invention comprehend any method of administration that permits circulation of the o compounds in the body of the patient.
- the compounds and pharmaceutical compositions of the present invention may be used alone or in combination with other anti-viral compounds.
- compounds and pharmaceutical compositions of the present invention maybe used in a variety of drug 'cocktails', or combinations of three or more antiretroviral 5 agents, that can potently suppress viral replication and prevent or delay the onset of ALDS.
- the antiviral is first attached to the linker LI to form the antiviral-linker AV-Ll, which is followed by the reaction with protein Pr to form the complex of Formula I.
- the present invention also teaches that the reverse sequence as noted above may also be applicable for the preparation of the complex of Formula TI.
- Sequences of putative HTV fusion inhibitor peptides were modeled using the crystal structure of the gp41 trimeric helical fusogenic complex (reviewed in Jiang et al, 2002). Peptide sequences were modeled to form helical segments that can fit into the grooves formed by the N-tenninal triple helical core of the fusogenic complex. 5 Evaluation of the inner binding and outer exposed surfaces of the modeled helical peptides were used to determine the sequence and composition of amino acids in the model peptides. Amino acids that have exposed side chains after complex formation are varied to improve solubility and other physical-chemical characteristics of the model peptide. Amino acids that bind to the N-terminal triple helical core are o determinative of binding affinity and antiviral activity.
- TCTU O-( 1 H-6-Chlorobenzotriazole- 1 -yl)- 1 , 1 ,3 ,3-teframethyluronium tetrafluoroborate
- DTEA diisopropylethylamine
- Antiviral potency of the peptides was analyzed against HTV-1 HXB2 or NL4-3 strains using a cytotoxicity assay with MT4 cells as previously described (ref 1-3) with minor modifications.
- MT-4 cells 1.5xl0 4 /ml were exposed to 200 50% tissue culture infective doses (TCID50) of viruses in the presence of various concentrations of test compound in 96 well microtiter plates and incubated at 37°C for 5 days.
- Cytotoxicity of HTV was measured by the addition of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide (MTT) solution to each well to a final concentration of 0.75 mg/ml, and incubation for 1 hour a 37°C. After incubation, cells were dissolved in isopropanol/Triton-X 100/HCl (1000:50:25) solution. Absorbance was monitored in a microplate reader (Spectramax, Molecular Devices) at 540 nm and 690 nm.. MT-4 cells were obtained from the ADDS Research and Reference Reagent Program (ARRRP, Division of ADDS, NIADD, NTH: MT-4 from Dr. D. Richman).
- ARRRP ADDS Research and Reference Reagent Program
- Example 3a Preparation of chemically-reactive modified HIV fusion inhibitor peptides.
- Analogues of peptides 2 and 7 demonstrate the general applicability of the procedure for enhancing the pharmacokinetic activity of peptides with diverse sequences.
- SPI-30014 and SPI-70038 (see below, Table 2) were prepared using solid phase synthesis techniques as described above. Instead of acetylating the N- terminus it is reacted with Fmoc-8-amino-3,6-dioxaoctanoic acid, TCTU, DTEA for
- Example 3b Preparation of quenched, modified HIV fusion inhibitor peptides.
- HSA-peptide conjugates SPI-30014HSA and SPI-70038HSA, were tested for antiviral and pharmacokinetic profile compared to the reactive intermediates (SPI-30014 and SPI-70038) and the quenched, unconjugated peptides (SPI-30014Q and SPI-70038Q).
- Example 5 Evaluation of antiviral activity of modified and conjugated HIV fusion inhibitor peptides.
- Antiviral potency of maleimide containing peptides; quenched, unconjugated peptides; and, peptide-HSA conjugates was analyzed against HXB2 HTV-1 using a cytotoxicity assay with MT4 cells as described in Example 2. IC 50 values for these compounds are listed in Table 2. The activities of the reactive and quenched peptides are similar. The antiviral activity of each HSA-peptide conjugates is reduced by about 3-4 fold.
- Linker - refers to maleimidopropionylaminoethoxyethoxyacetyl
- Example 6 Evaluation of pharmacokinetic properties of long-acting HIV fusion inhibitors.
- Peptide-HSA conjugates SPI-30014HSA and SPI-70038HSA
- quenched, unconjugated peptides SPI-30014Q and SPI-70038Q
- Test compounds were formulated in DMSO (peptides) or phosphate-buffered saline
- HSA-peptide conjugates were administered intravenously in a single dose of
- Serum samples were collected at 5 min, 30 min, 1, 2, 8, 24, 48, and 72 hours post dose.
- concentrations of antiviral peptides and conjugates in the rat plasma were analyzed using a cell-based antiviral bioassay. For each time point the serum sample was initially diluted 1:10 with growth medium and subsequently used for multiple serial dilutions analyzed in the standard antiviral assay using MT4 cells and HJV-l HXB2 virus described above.
- the IC50 value was detennined and expressed as the percent of sample serum necessary to inhibit 50% of the cytotoxic activity of HTV-1 HXB2.
- a reference sample was prepared that contains predose serum of the conesponding animal diluted 10-fold by medium. To this diluted sample a defined concentration of peptide or peptide-HSA conjugate in aqueous DMSO was added. This sample was then analyzed in the antiviral assay in the same way as test time point samples. This IC 50 reference value was determined and expressed as a concentration of peptide or peptide-HSA conjugate. The concentration of peptide or peptide-HSA conjugate in each test time point serum sample was then calculated based on the IC 50 values obtained with the reference sample in the serum from the conesponding animal:
- the concentration vs time profiles of test compounds in rat plasma are shown in Figs. 2 and 3 (average of 2-3 rats).
- the unconjugated (control) peptides display a rapid clearance profile: by 8 hours 80% of peptide is lost.
- the terminal half-life of the two HSA-peptide conjugates ranged from 12 to 14 hours.
- the half-life of the HSA-peptide conjugates is similar to the reported half-life of HSA alone in rodents (15.8 hours) (1 ). 1.
- a 10 mM solution of maleimidopropionylaminoethoxyethoxyacetyl derivatized antiviral peptide in DMSO was added to a 25% water solution of HSA.
- the final peptide concentration in the reaction mixture was 1 mM and the molar ratio in reaction mixture of peptide: HSA was 1 :4.
- the solution was incubated 5 hours at 37 °C. Once incubation was complete, the conjugate was stored at 4 °C.
- a 10 mM solution of N-(3- ⁇ 2-[2-(3-amino-propoxy)-ethoxy]-ethoxy]-ethoxy ⁇ - propyl)-2-bromoacetamide derivatized antiviral peptide in DMSO is added to a 25% water solution of HSA.
- the final peptide concentration in the reaction mixture is 1 mM and the molar ratio in reaction mixture of peptide: HSA is 1 :4.
- the solution is incubated 5 hours at 37 °C. Once incubation was complete, the conjugate is stored at 4 °C.
- a 10 mM solution of maleimidopropionylaminoethoxyethoxyacetyl derivatized antiviral peptide in DMSO is added to a 25% water solution of HSA.
- the final peptide concentration in the reaction mixture is 1 mM and the molar ratio in reaction mixture of peptide: HSA is 1:1.
- the solution is incubated 5 hours at 37 °C. Once incubation is complete, the conjugate is stored at 4 °C.
- a 10 mM solution of maleimidopropionylaminoethoxyethoxyacetyl derivatized antiviral peptide in DMSO is added to a 25% water solution of HSA.
- the final peptide concentration in the reaction mixture is 1 mM and the molar ratio in reaction mixture of peptide: HSA is 10:1.
- the solution is incubated 5 hours at 37 °C. Once incubation is complete, the conjugate is stored at 4 °C.
- Example 12 Binding Assay for peptidyl inhibitors of HIV fusion
- the binding affinity of conjugated inhibitors of HTV fusion is measured using a chimeric peptide (IQN17) that contains a segment of GCN4 at the N- terminal and 17 residues from the first heptad repeat region of HTV-1 GP41 at the C- terminal (Cell 99, 103-115).
- IQN17 chimeric peptide
- a 28-residue peptide from the second heptad repeat region of GP41 (C28) is labeled with a fluorescent molecule Alexa-430 (Molecular Probes) at its carboxyl terminal.
- the binding is measured by tifration of labeled C28 with IQN17.
- the concentrations of bound and unbound C28 were measured by capillary zone electrophoresis. At 3 ⁇ M C28 and 8 ⁇ m IQN17, about 80 % C28 is bound to IQN17. For unlabeled peptides, the amount that competes 50 % C28 off IQN17 gives its IC50 value.
- the present invention relates to biologically active compounds that may be used to react with proteins to form covalently linked complexes wherein the resulting complexes are found to exhibit renin inhibition activities in vivo. More specifically, the complexes are isolated complexes comprising a renin inhibitor and a linking group, and the blood component is a protein such as albumin.
- the present mvention also provides methods for inhibiting renin activity in vivo comprising administering to the bloodstream of a mammalian host the novel isolated complexes of the present invention.
- a pharmaceutical composition that comprises a purified renin inhibitor complex according to the present invention as an active ingredient.
- Pharmaceutical compositions according to the invention may optionally comprise 0.001%-100% of one or more renin inhibitors complexes of this invention.
- These pharmaceutical compositions may be administered or coadministered by various methods known in the art for administering biologically active agents to the bloodstream.
- the compositions may be administered by injection, hi another prefened aspect, the compositions may be administered by infusion.
- methods and compositions are provided for delivery of isolated conjugated complexes comprising biologically active agents, particularly therapeutic agents such as renin inhibitors, where the complexes comprising the agents have an extended half-life in the bloodstream as compared to non-conjugated agents.
- the invention comprises using a biologically active compound covalently attached or linked to a linking group, the linking group comprising at least one chemically reactive moiety which is capable of forming covalent bonds with functionalities present on the protein.
- the invention provides an isolated complex of the l o Formula I or Formula U:
- Di is a renin inhibitor
- LI and L2 are polyvalent linkers covalently linking Th to Pr, or where LI and 20 L2 are absent;
- Pr is a protein; and wherein the complex possesses renin inhibitory activity in vivo.
- the renin inhibitor Th is a peptide.
- the peptide has a mass of less than about 60 kDA.
- the peptide has a mass of less than about 10 kDA.
- the peptide has a mass of less than about 1000 DA.
- the peptide is a peptide mimetic.
- the peptide is a transition state mimetic at the C-terminus.
- the transition state mimetic at the C-terminus is selected from the group consisting of
- Hi is a renin inhibitor peptide selected from the group consisting of Iva-Val-Val-Sta-Ala-Sta, Boc-Phe-His-Sta-Ile-AMP, Boc-Phe- His-Sta-Ala-Sta-OMe, Boc-Phe-His-Sta-Leu-NHCH2Ph, Boc-Phe-His-ACHPA- 5 Leu-AMB, Boc-Phe-His-Sta-Leu-AMB, Boc-Pro-Phe-His-Sta-Ile-AMP, Iva-Phe- Nle-Sta-Ala-Sta, Iva-His-Pro-Phe-His-Sta-Ala-Sta, Iva-His-Pro-Phe-His-Sta-Leu- Phe-NH2, Ac-His-Pro-Phe-Val-Sta-Leu-Phe-NH2, Ac-His-Pro-Phe
- Phe-Phe-Val-Tyr-Lys His-Pro-Phe-His-Leu-D-Leu-Val-Tyr-OH, Pro-His-Pro-Phe- His-Leu(CH2NH)Val-Ue-His-Lys (H-142), Boc-Phe-His-Cha-(CH2NH)Val- NH2(S)-Me(Bu), Pro-His-Pro-Phe-His-Leu-Phe-Val-Tyr-OH, Boc-His-Pro-Phe- His-Leu(CH(OH)CH2)Val-Ile-His-OH (H-261), and PEC-Phe-His- 5 ACHPA-TLeNHC(CH2OH)2CH3.
- Hi is a renin inhibitor peptide selected from the group consisting of Iva-Val-Val-Sta-Ala-Sta, Boc-Phe-His-Sta-Ile-AMP, Boc-Phe- His-Sta-Ala-Sta-OMe, Boc-Phe-His-Sta-Leu-NHCH2Ph, Boc-Phe-His-ACHPA- Leu-AMB, Boc-Phe-His-Sta-Leu-AMB, Boc-Pro-Phe-His-Sta-Ile-AMP, Iva-Phe- o Nle-Sta-Ala-Sta, Iva-His-Pro-Phe-His-Sta-Ala-Sta, Iva-His-Pro-Phe-His-Sta-Leu-
- the linker LI or L2 comprises at least two 5 functional groups covalently linking Hi to Pr.
- the linker LI or L2 is hydrolytically stable in human serum for an extended period of time.
- the linker is sufficiently hydrolytically stable that, when administered to a subject, the active conjugate produces a sustained decrease in blood pressure over an extended period of time.
- the linker is sufficiently stable 0 that the conjugate can produce a sustained decrease in blood pressure for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days or more, or 14 days or more.
- the linker LI or L2 is stable in human serum for half lives of between 8 hours and 30 days.
- the linker LI or L2 is a derivative 5 of a compound selected from the group consisting of acyloxymethylketones, aziridines, diazomethyl ketones, epoxides, iodo-, bromo- or chloroacetamides, - haloesters, ⁇ -haloketones, sulfoniums, chloroethylsulfides, O-alkylisoureas, alkyl halides, vinylsulfones, acrylamides, acrylates, vinylpyridines, organometallic compounds, aryldisulfides, thiosulfonates, aldehydes, nitriles, ⁇ -diketones, ⁇ - o ketoamides, ⁇ -ketoesters, diaminoketones, semicarbazones, and dihydrazides.
- acyloxymethylketones aziridines, diazomethyl ketones, epoxides, i
- the linker LI or L2 is a derivative of a compound selected from the group consisting of azidobenzoyl hydrazide, N-[4-(p- azidosalicylamino)butyl] -3 '-[2'-pyridyldithio)propionamide), bis-sulfosuccinimidyl suberate, dimethyl adipimidate, disuccinimidyl tartrate, N-y- 5 maleimidobutyryloxysuccinimide ester, N-hydroxy sulfosuccinimidyl-4- azidobenzoate, N-succinimidyl [4-azidophenyl]-l,3'-dithiopropionate, N- succinimidyl [4-iodoaceryl]aminobenzoate, glutaraldehyde, succinimidyl 4-[N- maleimidomethyl]cyclohexane-l-car
- the protein is selected from the group consisting of red blood cells, and immunoglobulins, such as IgM and IgG, serum albumin, fransferrin, p90 and p38.
- the protein is albumin.
- the albumin is HSA or recombinant HSA that is at least 10% pure on a dry matter basis.
- the linkage is to a Cys- 34 of human albumin.
- the linkage is to a lysine of human albumin.
- the invention provides a complex of Formula I or
- the complex is prepared by combining a stoichiometric ratio of (Ih)m-Ll with Pr or a stoichiometric ratio of JJi with L2-(Pr)o. In another variation, the complex is prepared by combining a mixture of Pr to (Ih)m-Ll in a ratio of at least about 1.3 : 1. hi another embodiment, the invention provide the complex of Formula I or
- the complex is prepared by forming an activated intermediate of Hi followed by the condensation of the activated Hi intermediate with Pr.
- the activated intermediate of Hi is prepared from a mixed anhydride or N,N'-carbonyldiimidazole reagent.
- the complex may be further purified to a purity of at least about 30%.
- the renin inhibitor is a peptidomimetic with a mass of less than about 1000 DA.
- compositions comprising the complex of Formula I or Formula II and a physiologically acceptable carrier.
- the composition above is formulated for parenteral administration.
- the composition above is selected from the group consisting of solutions, dry products for combining with a solvent prior to use, suspensions, emulsions, and liquid concentrates.
- the invention provides a method for inhibiting renin 5 activity in vivo, said method comprising: administering to the bloodstream of a mammalian host an isolated conjugate complex of Formula I or Formula II, wherein the complex is formed by attaching a renin inhibitor to a linker having at least one reactive functional group which reacts with the protein to form stable covalent bonds; and o wherein the isolated conjugate complex is administered in an amount to maintain an effective therapeutic effect in the bloodstream for an extended period of time as compared to a non-conjugated renin inhibitor.
- the invention provides a method wherein the complex is the complex according to any of the above complexes.
- the protein is HSA or recombinant HSA.
- the linker comprises a reactive functional group is a compound selected from the group consisting of acyloxymethylketones, aziridines, diazomethyl ketones, epoxides, iodo-, bromo- or chloroacetamides, ⁇ -haloesters, cc-haloketones, sulfoniums, chloroethylsulfides, O- o alkylisoureas, alkyl halides, vinylsulfones, acrylamides, acrylates, vinylpyridines, organometallic compounds, aryldisulfides, thiosulfonates, aldehydes, nitriles, - diketones, ⁇ -ketoamides, ⁇
- the invention provides a method for inhibiting renin activity 5 in vivo, said method comprises: administering into the bloodstream of a mammalian host the complex of Formula I or Formula II in an amount sufficient to provide an effective amount for renin inhibition; whereby said complex is maintained in the bloodstream over an extended o period of time as compared to the lifetime of unbound renin inhibitor.
- a method for inhibiting renin activity in a host said method comprising: a) preparing a compound Th-Ll or H ⁇ -L2 wherein Hi is a renin inhibitor peptide with a mass of less than 60 kD and LI or L2 is a linker covalently bound to
- the protein is albumin.
- the albumin is HSA or recombinant HSA.
- the albumin is obtained from blood, purified and isolated from blood prior to treating the albumin with the compound Hi-Ll or H ⁇ -L2.
- the albumin is purified to a purity level of at least 10% on a dry matter 5 basis, hi yet another variation, the albumin is purified to a purity level of more than 95%.
- the invention provides a method for inhibiting renin activity in a host, said method comprising: a) preparing a compound Hi-Ll or H ⁇ -L2 wherein Hi is a renin inhibitor o peptide with a mass of less than 60 kD and LI or L2 is a linker covalently bound to
- the protein is albumin.
- the albumin is obtained from blood, purified and isolated from blood prior to treating with the compound Hi-Ll or Ih-L2.
- the albumin is HSA or recombinant HSA.
- a phannaceutical composition comprising a therapeutically effective amount of a complex as describe above, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent, fri another variation, there is provided a method of reducing the blood pressure of a subject comprising administering to the subject a therapeutically effective amount of the above composition.
- the invention provides the above method, wherein the patient suffers from hypertension.
- the patient suffers from mild, moderate or severe hypertension.
- the transition state mimetic is a compound of the formula:
- R is selected from the group consisting of (C ⁇ - ⁇ o)alkyl, (C 6 - ⁇ 2 )cycloalkyl, carbonyl(C ⁇ - ⁇ o)alkyl, sulfonyl(C ⁇ -3 )alkyl, sulfinyl(C ⁇ -3 )alkyl, (C 2- ⁇ 2 )alkenyl, (C 2- ⁇ 2 )alkynyl, aryl, aryl(C ⁇ - ⁇ o)alkyl, heteroaryl, heteroaryl(C ⁇ - ⁇ 0 )alkyl, each substituted or unsubstituted; and
- R' is selected from the group consisting of (C ⁇ - ⁇ o)alkyl, (C 6- ⁇ 2 )cycloalkyl, carbonyl(C ⁇ - ⁇ o)alkyl, (C ⁇ - ⁇ o)alkoxycarbonyl, (C ⁇ -1 o)alkylaminocarbonyl, sulfonyl(C ⁇ -3 )alkyl, sulfinyl(C ⁇ -3 )alkyl, (C 2- ⁇ 2 )alkenyl, (C 2- ⁇ 2 )alkynyl, aryl, aryl(C ⁇ - ⁇ o)alkyl, heteroaryl, heteroaryl(C ⁇ - ⁇ o)alkyl, alkylsulfonyl(C ⁇ - ⁇ o)alkyl, arylsulfonyl(C ⁇ . ⁇ o)alkyl, heteroarylsulfonyl(C ⁇ . ⁇ o)alkyl, (C ⁇ . ⁇ o)alkylphosphonate and (
- transition state mimetic is a compound of the formula: wherein:
- R is selected from the group consisting of (C ⁇ - ⁇ o)alkyl, (C 6 - ⁇ 2 )cycloalkyl, carbonyl(C ⁇ . ⁇ o)alkyl, sulfonyl(C ⁇ - )alkyl, sulfinyl(C ⁇ -3 )alkyl, (C 2- ⁇ 2 )alkenyl, (C 2- ⁇ 2 )alkynyl, aryl, aryl(C ⁇ - ⁇ o)alkyl, heteroaryl, heteroaryl(C ⁇ -1 o)alkyl, each substituted or unsubstituted; and
- R" is selected from the group consisting of (C ⁇ alkyl, (C 6 - ⁇ 2 )cycloalkyl, heterocycloalkyl, bicycloalkyl, carbonyl (C ⁇ - ⁇ o)alkyl, thiocarbonyl (C ⁇ - )alkyl, sulfonyl (C 1- )alkyl, sulfinyl(C ⁇ -3 )alkyl, amino, imino(C 1-3 )alkyl, (C ⁇ . ⁇ o)alkoxy, aryloxy, heteroaryloxy, (C 2- ⁇ 2 )alkenyl, (C 2- ⁇ 2 )alkynyl, aryl, aryl(C ⁇ - ⁇ o)allcyl, heteroaryl, heteroaryl(C ⁇ - ⁇ o)alkyl, (C 9 - ⁇ 2 )bicycloaryl, hetero(C8- ⁇ 2 )bicycloaryl, aminosulfonyl, alkylsulf
- R is selected from the group consisting of (C ⁇ - ⁇ o)alkyl, (C 6 - ⁇ 2 )cycloalkyl, carbonyl(C i. ⁇ alkyl, sulfonyl(C ⁇ -3 )alkyl, sulfinyl(C ⁇ -3 )alkyl, (C 2- ⁇ 2 )alkenyl,
- R" is selected from the group consisting of heterocycloalkyl, bicycloalkyl, carbonyl (C ⁇ . ⁇ o)alkyl, thiocarbonyl (C ⁇ -3 )alkyl, sulfonyl (C ⁇ -3 )alkyl, sulfinyl(C ⁇ - )alkyl, amino, imino(C ⁇ - )alkyl, (C ⁇ - ⁇ o)alkoxy, aryloxy, heteroaryloxy, (C 2-12 )alkenyl, (C 2- ⁇ 2 )alkynyl, aryl, aryl(C]. ⁇ 0 )alkyl, heteroaryl, hetero(Cs-i 2 )bicycloaryl, aminosulfonyl, alkylsulfonyl, alkylsulfonyl(C ⁇ - ⁇ o)alkyl, arylsulfonyl, arylsulfonyl(C]- ⁇ o)al
- transition state mimetic is a compound of the formula:
- R is selected from the group consisting of (C ⁇ . ⁇ o)alkyl, (C 6 - ⁇ 2 )cycloalkyl, carbonyl(C ⁇ - ⁇ 0 )alkyl, sulfonyl(C ⁇ -3 )alkyl, sulfinyl(C ⁇ -3 )alkyl, (C 2- ⁇ 2 )alkenyl, (C 2- ⁇ 2 )alkynyl, aryl, aryl(C ⁇ - ⁇ o)alkyl, heteroaryl, heteroaryl(C ⁇ - ⁇ o)alkyl, each substituted or unsubstituted; and
- R" is selected from the (C 6 - ⁇ 2 )cycloalkyl, heterocycloalkyl, bicycloalkyl, carbonyl (C ⁇ . ⁇ o)alkyl, thiocarbonyl (C ⁇ -3 )alkyl, sulfonyl (C ⁇ -3 )alkyl, sulf ⁇ nyl(C ⁇ -3 )alkyl, amino, imino(C] -3 )alkyl, (C ⁇ . ⁇ o)alkoxy, aryloxy, heteroaryloxy, (C - ⁇ 2 )alkenyl, (C 2- ⁇ )alkynyl, aryl, aryl(C ⁇ - ⁇ o)alkyl, heteroaryl, heteroaryl(C ⁇ - ⁇ o)alkyl, (Cg.i ⁇ bicycloaryl, and hetero(C 8 - ⁇ 2 )bicycloaryl, each substituted or unsubstituted.
- the present invention relates to compounds and compositions
- the invention comprises using a biologically active compound covalently attached or linked to a linking group, the linking group comprising at least one chemically reactive moiety which is capable of forming covalent bonds with functionalities present on a protein or a blood protein.
- the protein is albumin.
- the extended life-time at a useful dosage will usually be at least 2 days, more preferably at least 5 days, even more preferably, at least 10 days, and most 5 preferably at least 15 days.
- the protein that may be conjugated to include red blood cells, immunoglobulins, such as IgM and IgG, serum albumin, fransferrin, p90 and p38. hi a prefened embodiment, the protein is albumin, hi another embodiment, the protein is recombinant albumin.
- the protein has a number of different functional groups which may react with the inhibitor-linking group compound to form a complex of Formula I:
- the protein has a number of different functional groups which may react with the inhibitor-linking group compound to form a 2 o complex of Formula JJ:
- Ih is a biologically active agent
- LI and L2 are linking groups that link Hi to Pr
- Pr is a blood component
- m and o are integers from 1-5
- n and p are integers from 1-100. 25
- a number of functional groups are available on the protein such as albumin.
- Non-limiting functional groups include amino groups, carboxyl groups and thio groups. While any of these functional groups in the protein may be employed to form a covalent bond with the linker group, depending on the nature of the functional group(s) on the linking group and the linker, certain functional groups will be prefened over the others. For example, the reaction of amine groups may form conjugates having an amide group, carboxyl groups may form conjugates having an amide or ester groups, and thio groups may form thioethers or thioesters.
- the biologically active agent Hi may be any compound, such as an enzyme inhibitor, that will elicit a desired biological response and induce minimal immune response when administered in a mammalian host.
- the biologically active agent is a renin inhibitor. More preferably, the agent is a peptide or l o peptidomimetic renin inhibitor.
- a large variety of renin inhibitors may be used in the present invention. Non-exclusive examples of peptide or peptidomimetic renin inhibitors are shown in the Table.
- the renin inhibitors are peptidomimetics with a mass of less than about 60 kDA, more preferably less than about 10 kDA, and most preferably less than about 1000 DA.
- linkers or linking groups LI and L2 may be used to link the blood component with the renin inhibitor.
- the linking groups may be divalent or polyvalent.
- LI may be n- 5 valent where it is attached to Pr, and m-valent where it attaches to Hi where m and n are integers as defined above.
- L2 may be o- valent where it is attached to Pr and p-valent where it is attached to Hi, where o and p are as defined above.
- Non-exclusive examples of functional groups that may be present in a linking group include compounds that have a hydroxyl groups, such as o N-hydroxysuccinimide, N-hydroxysulfosuccinimide, and other compounds such as maleimide-benzoyl-succinimide, ⁇ -maleimido-butyryloxy succinimide ester, maleimidopropionic acid, N-hydroxysuccinimide, isocyanate, thioester, thionocarboxylic acid ester, imino ester, carbodiimide, anhydride, or ester.
- a hydroxyl groups such as o N-hydroxysuccinimide, N-hydroxysulfosuccinimide, and other compounds such as maleimide-benzoyl-succinimide, ⁇ -maleimido-butyryloxy succinimide ester, maleimidopropionic acid, N-hydroxysuccinimide, isocyanate, thioester
- linking groups having functional groups such as 5 carboxylate, acid halide, azido, diazo, carbodiimide, anhydride, hydrazine, aldehydes, thiols, or amino group may be used to form amides, esters, imines, thioethers, disulfides, substituted amines, or the like.
- acyloxymethylketones examples include acyloxymethylketones, aziridines, diazomethyl ketones, epoxides, iodo-, bromo- or chloroacetamides, ⁇ -haloesters, - o haloketones, sulfoniums, chloroethylsulfides, O-alkylisoureas, alkyl halides, vinylsulfones, acrylamides, vmylpyridines, organometallic compounds, aryldisulfides, thiosulfonates, aldehydes, nitriles, ⁇ -diketones, c-ketoamides, a- ketoesters, diaminoketones, semicarbazones, and dihydrazides.
- the nature and type of compounds that may be selected as the linker 5 depends on the type of reactions, the relative reactivities, selectivities, reversibility and stability characteristics that are desired among the renin inliibitors, the linker and the functional groups on albumin or the blood component.
- certain reactions that form the conjugate complex arise from an alkylation reaction, a Michael type reaction, an addition-elimination reaction, an addition to sulfur, o carbonyl, or cyano groups, or the formation of a metal bond.
- the covalent bond that is formed from these reactions are stable during the active lifetime of the renin inhibitor. In one embodiment, the covalent bond that is formed in these complexes remain stable unless the biologically active subunit is intended to be released at the active site.
- the linkers may comprise of compounds having bifunctional or polyfunctional groups that are available for linking a protein such as albumin to multiple renin inhibitors or for linking multiple albumins to a single renin inhibitor.
- the linker comprises polyfunctional groups that link a HSA to one or more renin inhibitors.
- linking o compounds as used herein include any compounds that can link the renin inhibitor to the protein in a single step, hi another embodiment, the linking compounds are linked to the renin inhibitor first to form a inhibitor-linker intermediate that can be further reacted with the protein, hi another embodiment, the linking compounds are reacted with the protein first to form a protein-linker intermediate that can be further 5 reacted with the renin inhibitor, hi each of the above pennutations, optionally, the linked compounds may be further purified and/or isolated before submitting to further reactions to form the complex of Formula I or Formula ⁇ .
- Non-exclusive examples of such polyfunctional compounds include compounds having at least one functional group selected from the group consisting 0 of azidobenzoyl hydrazide, N-[4-(p-azidosalicylamino)butyl]-3'-[2'- pyridyldithio)propionamide), bis-sulfosuccinimidyl suberate, dimethyl adipimidate, disuccinimidyl tartrate, N-y-maleimidobutyryloxysuccinimide ester, N-hydroxy sulfosuccinimidyl-4-azidobenzoate, N-succinimidyl [4-azidophenyl]-l,3'- dithiopropionate, N-succinimidyl [4-iodoacetyl]aminobenzoate, glutaraldehyde, and 5 succinimidyl 4-[N-maleimidomethyl]cyclohexane
- linker or linking group that is convenient for use and subject to standard chemical transformations, or linkers that form compounds that are physiologically acceptable at the desired dosages, and are stable in the bloodsfream for the desired period of time, may be employed.
- the linking group may be aliphatic, alicyclic, o aromatic, heterocychc, or combinations thereof.
- groups that may be employed as a linking group include alkylenes, arylenes, aralkylenes, cycloalkylenes, polyethers and the like.
- polyfunctional polyethylene glycol (PEG) and their derivatives may also be employed as linkers.
- the linking groups may have at least one atom in the linking chain, more preferably between 1 and 200 atoms in the chain, most preferably between 2 and 50 5 atoms in the chain.
- the atoms in the chain can be linear or the chain can be part of one or more rings, each substituted or unsubstituted, and the chain may include carbons or heteroatoms selected from the group consisting of O N, P and S.
- the rings maybe aliphatic, heterocylic, aromatic or heteroaromatic or mixtures thereof, each substituted or unsubstituted.
- amino acids or peptides or o amino acids employed with mixtures of the above may be used as a linking group.
- LI is absent and Hi is attached directly to Pr.
- L2 is absent and Hi is attached directly to Pr.
- LI is a linking group that is capable of linking more than one Hi to one Pr, for example, where m is 2 or 5 more. In one embodiment, m is 1, 2 or 3 and n is 1-30. h one prefened embodiment for the complex of Formula I, Pr is albumin and n is 1. hi another particular embodiment, Pr is albumin, Hi is a renin inhibitor, and n is 2 - 25. hi another embodiment for the complex of Formula ⁇ , L2 is a linking group that is capable of linking more than one Pr to one Hi, for example, in the case where 0 o is 2 or more. In one embodiment, Pr is albumin, Hi is a renin inhibitor, o is 1 , 2 or 3 and p is 1-5.
- the linking group may be absent in cases where the inhibitor, such as a renin inhibitor, can be reacted directly with a protein, optionally using a catalyst or coupling agent, such that the complex that is formed comprises 5 only of the renin inhibitor that is directly attached to the protein.
- a direct coupling reaction is a mixed anhydride activated coupling reaction of a carboxylic acid followed by the coupling reaction of the intermediate mixed anhydride.
- the Protein Component Pr o
- Naturally occurring blood components include blood proteins, which include red blood cells, and immunoglobulins, such as IgM and IgG, serum albumin, fransferrin, p90 and p38.
- the blood component or blood protein is albumin. More preferably, the albumin is a protein human serum albumin (HSA).
- HSA human serum albumin
- the albumin used in the present invention may also be recombinant albumin.
- the recombinant human albumin may be produced by transforming a microorganism with a nucleotide coding sequence encoding the amino acid sequence of human serum albumin.
- Albumin is the main protein present in blood plasma, and may be extracted from blood, for examples as disclosed in JP 03/258 728, EP 428 758, EP 452 753, and 6,638,740 and references cited therein.
- Further examples of non-exclusive methods for the isolation of various compounds may be based on selective reversible precipitation, ion exchange chromatography, protein affinity chromatography, hydrophobic chromatography, thiophilic chromatography (J. Porath et al; FEBS Letters, vol. 185, p.306, 1985; K. L.
- the linked compounds Hi-Ll or H ⁇ -L2 of the present invention may be prepared and used in the conjugation with albumin without further purification and/or isolation.
- the purity of the linked compounds will depend on the nature of the linker, the nature of Hi, and the type of reaction and reaction conditions employed to attach Hi to the linker.
- the unpurified linked compounds are prepared and obtained with a purity of at least 90%, preferably at least 95%, more preferably at least 97%, and most preferably at least 98%.
- the present invention relates to methods for the preparation of the isolated linked compounds, that is, Hi-Ll or fl ⁇ -L2.
- the isolated linked compounds fli-Ll and H ⁇ L2 are renin inhibitors that are attached to a linker.
- the isolated linked compounds may be purified before conjugating with Pr.
- the linked compounds Hi-Ll or H ⁇ -L2 are isolated and purified to a purity of at least 95%, 5 preferably at least 97%, more preferably at least 98%, and most preferably at least 99% or more.
- the linked compounds may be prepared using standard methods known in the art of chemical synthesis.
- the compounds may be purified using standard methods known in the art, such as by column chromatography or HPLC to provide l o purified products suitable for in vivo applications.
- the linked compounds may be further conjugated with a protein, such as albumin to form the complex of Formulae I and ⁇ .
- Pr 15 represented by Pr may be albumin, may be used as obtained from commercial sources without further purification or isolation, to prepare the linked compounds Pr-Ll and Pr-L2.
- Pr is HSA.
- the albumin may be further purified using various methods known in the art as disclosed herein.
- the linked compounds Pr-Ll and Pr-L2 may be prepared by treating a linker LI or L2, which may be derivatized or activated, with Pr, in a solution and monitoring the reaction mixture until the reaction is substantially complete, hi a particular prefened embodiment, Pr is a protein, hi another prefened embodiment, the protein is HSA or recombinant HSA.
- the linked compounds Pr-Ll or Pr-L2 obtained are substantially pure; that is, the linked compounds are obtained with a purity of at least 10%, preferably at least 30%, and more preferably at least 50%.
- the Pr is HSA or recombinant HSA
- components that may be present with the linked compounds may comprise of unreacted HSA and various biological
- the HSA or recombinant HSA is at least 10% pure on a dry matter basis.
- An excess of HSA or HSA related biologically materials present with the linked compounds will not significantly interfere with the subsequent conjugation step with Th.
- the related biological materials and the conjugated complexes will also be pharmacologically safe for use in vivo.
- the purity of the linked compounds Pr-Ll or Pr-L2 may be at least 10% on a dry matter basis to enable the selective reaction of the compounds with Hi without a significant amount of interferences or without the formation of undesirable by-products obtained from the conjugate reaction with other undesired blood components.
- the desired purity of Pr such as HSA 0 or recombinant HSA, for example, will depend on the nature of the functional groups on Hi as well as the functional groups employed on the linker. Typically, higher purities of HSA or recombinant HSA is required if the functional groups on the linker are more reactive and may form undesired by-products than functional groups on the linker that are less reactive.
- the albumin may be obtained from plasma or blood albumin from a host, purified to a desired level of purity, and linked with the linker. Purification of the albumin from blood or blood plasma may be performed using well established standard methods known in the art for the purification of albumin. Using purified blood albumin, the isolated complexes of the present will comprise of a relatively o homogeneous population of functionalized proteins.
- the complexes of Formula I or Formula II may be prepared by the conjugation of Hi-Ll or H ⁇ -L2 with Pr, the conjugation of Pr-Ll or Pr-L2 with Th, or the conjugation of Hi with Pr to form a complex wherein the linker 5 is absent.
- a solution of Hi-Ll or H ⁇ -L2 is combined with Pr under conditions such that the conjugation reaction is deemed to be complete.
- the linked compound is a renin inhibitor that is attached to a linker, and the linked compound is added to an aqueous solution of HSA. The o resulting solution is incubated until the reaction is substantially complete.
- the Hi-Ll or H ⁇ -L2 is combined with an excess of HSA to ensure that the conjugation reaction proceeds selectively to a single site on the HSA. For example, the formation of Hi-Ll on a single site on HSA may permit ease of identification of a single complex of Formula I, for example, where n is 1.
- the conjugate reaction of Hi-Ll or H ⁇ -L2 with HSA occurs on a single cysteine of HSA.
- the conjugate reaction may also occur initially with a cysteine -SH group to form a kinetic product that is then reananged to another amino acid functional group, such as a lysine, to form the thermodynamic product.
- the conjugate reaction may form the complex of
- the complex of Formula I may be 5 prepared by combining an excess of Pr relative to (B ⁇ )m-Ll .
- the ratio of Pr to (H ⁇ )m-Ll is about 50 to 100.
- the ratio is from about 10 to 30.
- the ratio is from about 2 to 5.
- Pr is added to (fl ⁇ )m-L 1 in a ratio of at least about 1.1:1, o more preferably at least about 1.2: 1 , and most preferably at least about 1.4: 1.
- the prefened ratios are based on the assumption that there is 0.7 free thiol per albumin.
- the resulting complex is formed as a 1 : 1 complex, since a Pr component such as albumin has only about 70% free thiol functionality for conjugation.
- An excess of Pr, such as HSA or recombinant HSA is 5 pharmacologically safe and may not require further purification.
- the conjugated complex may be purified to a purity of at least 10%. In a particular embodiment, the conjugated complex may be purified to at least about 20% or at least about 30%.
- the complex of Formula I may be prepared by o combining an excess of (H ⁇ )m-Ll relative to Pr.
- Pr is about 50 to 100. In another particular embodiment, the ratio is from about 10 to 30. In yet another particular embodiment, the ratio is from about 2 to 5. Where there is an excess of (H ⁇ )m-Ll in the product mixture, optionally, the conjugated complex may be purified to a purity of at least 10%. In a particular embodiment, the conjugated complex may be purified to at least about 20% or at least about 30%. In another embodiment, the complexes of Formula I or Formula U may be prepared from a stoichiometric ratio of (H ⁇ )m-Ll with Pr or a stoichiometric ratio of Hi with L2-(Pr)o, that is, in a 1 : 1 ratio.
- the resulting product from these preparations may be further purified to a purity of at least 10%.
- the conjugated complex may be purified to at least about 20% or to a purity of at least about 30%.
- the 1 : 1 conjugated complex may be further purified to a purity of greater than about 90%.
- the conjugated cysteine present in albumin is reduced to the free cysteine prior to the reaction.
- the complex formed from the conjugate reaction may be further purified prior to administration.
- the complexes of Formula I or Fonnula U obtained from the conjugate reaction may be administered without further processing or purification since an excess of HSA or HSA related biologically materials present with the complexes are pharmacologically safe for use in vivo.
- Hi is a peptide or peptidomimetic renin inhibitor and Pr is HSA or recombinant HSA.
- the isolated complex comprising a protected or unprotected renin inhibitor with a linker and albumin may be optionally further purified and then returned to the host.
- the complexes formed from the methods of the present invention may be tested in animal or human hosts until the physiology, pharmacokinetics, and safety profiles are well established over an extended period of time.
- the measured half-life of the complexes is about 5 to 7 days, more typically at least about 7 to 10 days, and preferably 15 to 20 days or more.
- the duration is species dependent.
- the half life is about 17-19 days.
- the effective therapeutic concenfration of the complexes may be at least 1 month or more.
- Half lives may be determined by serial measurements of whole blood, plasma or serum levels of the complexes of Formula I or Formula ⁇ , the Hi-L 5 compounds, the L-Pr compounds, or the Hi compounds following labeling of the complex or compounds with an isotope (e.g., 1311, 1251, Tc, Cr, 3H, etc ...) or fluorochrome and injection of a known quantity of labeled complex or compound infravascularly. Included are red blood cells (half life ca.
- the subject components are preferably in cell count or concentration sufficient to allow binding of therapeutically useful amounts of the compound of the present invention.
- cell counts of at least 2,000/ ⁇ l and serum protein concentrations of at least 1 ⁇ g/ml, usually at least about 0.01 mg/ml, more usually at least about 1 mg/ml, are prefened.
- the desired half life for the effective therapeutic concenfration of the complex and/or the biologically active agent may vary from the measured half-life above.
- the rate of release of the biologically active agent depends in part, on the valency or the functionality on the biological agent which is to be released, the nature of the linking group, the purity and type of the protein, the 5 composition for administration, the manner of administration, and the like.
- linking groups and biological agents may be employed, where the environment of the blood, components of the blood, particularly enzymes, activity in the liver, or other agent may result in the cleavage of the linking group with release of the biological agent in the host at a desired rate.
- the isolated complexes of the present invention provides biological active compounds that have improved pharmacokinetics, solubility, bioavailabihty, distribution, and/or immunogenicity characteristics as compared to the non- conjugated compounds.
- the complexes of Formula I and Formula II when prepared and used according to the methods of the present invention, provides an effective 5 therapeutic concentration for a significantly longer time than the Hi component by itself.
- the complexes of the present mvention provide improved solubility, distribution, phannacokinetics, and result in decrease immunogenicity when compared to the administration of the Hi component by itself.
- the present inventors su ⁇ risingly have found that administration to a o subject of a conjugate that is prepared ex vivo from purified components
- a therapeutically effective amount of a composition is understood to mean an amount that, when administered to a subject, produces a desired physiological effect to a degree that is effective for treatment of a disease, condition, or syndrome in the patient, or tliat is effective in 5 alleviating the symptoms disease, condition, or syndrome.
- a therapeutically effective amount of an antihypertensive complex or composition is understood to mean an amount that, upon administration to a hypertensive subject, produces a desired reduction in systolic and/or diastolic pressure.
- the administration of the isolated complex of the present invention may be accomplished using a bolus, but may be introduced slowly over time by transfusion using metered flow, or the like.
- the complex of the present invention may be administered in a physiologically acceptable medium, e.g. deionized water, phosphate buffered saline, saline, mannitol, aqueous glucose, alcohol, vegetable oil, or the like.
- a single injection may be employed although more than one injection may be used, if desired.
- the complex may be administered by any convenient means, including 0 syringe, frocar, catheter, or the like. The particular manner of administration, will vary depending upon the amount to be administered, whether a single bolus or continuous administration, or the like.
- the administration may be infravascularly, where the site of introduction is not critical to this invention, preferably at a site where there is rapid blood flow, e.g. intravenously, peripheral or central vein.
- Other s routes may find use where the administration is coupled with slow release techniques or a protective matrix.
- the administration of the isolated complexes prepared by the methods of the present invention results in renin inhibitor conjugate complexes that o maintain an effective therapeutic effect in the bloodsfream for an extended period of time as compared to a non-conjugated renin inhibitor or as compared to complexes that are not prepared from isolated blood protein such as albumin.
- the present invention provides the compounds in the form of a pharmaceutically acceptable salt. 5 In another embodiment, the present invention provides the compounds present in a mixture of stereoisomers. In yet another embodiment, the present invention provides the compounds as a single stereoisomer. hi yet another embodiment, the present invention provides pharmaceutical compositions comprising the compound as an active ingredient. In yet another o particular variation, the present mvention provides pharmaceutical composition wherein the composition is a tablet or a solid for administration as a depot. In another particular variation, the present invention provides the pharmaceutical composition wherein the composition is a liquid formulation adapted for TV or subcutaneous administration, hi yet another particular variation, the present invention provides pharmaceutical composition wherein the composition is a liquid 5 formulation adapted for parenteral administration.
- Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention. For example, prodrugs can be prepared by o reacting a compound with a carbamylatmg agent (e.g.,
- Protected derivatives of compounds of the present invention can also be 5 made. Examples of techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
- Hydrates of o compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxane, tetrahydrofuran or methanol.
- a "pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the 5 form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound.
- the pharmaceutically acceptable salt fonn may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the o compound with respect to its therapeutic activity in the body.
- An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the abso ⁇ tion, distribution, biotransformation and excretion of the compound.
- Renin is an endopeptidase which plays an important 5 role in the control of blood pressure.
- the renin angiotension system is a multiregulated proteolytic cascade in which renin cleaves the protein substrate angiotensinogen to give angiotensin I.
- Angiotensin converting enzyme (ACE) catalyses the removal of the terminal dipeptide from the decapeptide angiotensin I to form angiotensm U which exhibits potent pressor activity.
- Renin is an aspartyl o protease with high substrate specificity and is the first proteolytic step in the renin- angiotensin system which is involved in the control of blood pressure. Renin 85505
- compositions designed to administer the renin inhibitors of the present invention by parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
- injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- excipients examples include, but are not limited to water, saline, dextrose, glycerol, ethanol, or DMSO.
- the injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
- Implantation of a slow-release or sustained-release system such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein.
- the percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
- Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations.
- Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.
- the solutions may be either aqueous or nonaqueous.
- suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures .thereof.
- suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures .thereof.
- pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
- aqueous vehicles that may optionally be used include Sodium
- Chloride Injection Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
- nonaqueous parenteral vehicles examples include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut 5 oil.
- Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed.
- antimicrobial agents tliat may be used include phenols or o cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p- hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
- Examples of isotonic agents that may be used include sodium chloride and dextrose.
- Examples of buffers that may be used include phosphate and citrate. 5
- antioxidants that may be used include sodium bisulfite.
- Examples of local anesthetics that may be used include procaine hydrochloride.
- Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpynolidone.
- emulsifying agents examples include Polysorbate 80 (TWEEN 0 80).
- a sequestering or chelating agent of metal ions include EDTA.
- Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
- the concentration of a renin inhibitor complex in the parenteral formulation 5 may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect.
- concentration of a renin inhibitor complex and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.
- parenteral preparations may be packaged in an ampule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is known and practiced in the art.
- Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least 5 about 0.1% w/w up to about 90% w/w or more, preferably more than 1% w/w of the renin inhibitor to the treated tissue(s).
- the renin inhibitor complexes may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is o parenterally administered, the carrier and other variables that may be detennined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data.
- concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time 5 according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concenfration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.
- the renin inhibitor complexes may optionally be suspended in micronized or o other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug.
- the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
- the effective concenfration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined. 5 Suitable formulations for each of these methods of administration may be found in, for example, "Remington: The Science and Practice of Pharmacy", A. Gennaro, ed., 20th edition, (2000), Lippincott, Williams & Wilkins, Philadelphia, PA.
- alkylating reagents iodoacetamide, 4-vinylpyridine, and acrylamide are all successful in improving the sequence coverage for albumin.
- Alkylation of Cysteines 20 Benzyl chlorides: Saunders; BIJOAK; Biochem. J.; 28; 1934; 1977; Kwon,
- Alkyl halide Foti, Salvatore; Saletti, Rosaria; Marietta, Donata; Org.Mass Spectrom.; EN; 26; 10; 1991; 903-907; Jin, Lixia; Baillie, Thomas A.; 25 Chem.Res.Toxicol.; EN; 10; 3; 1997; 318 - 327; Franzen, Henry M.; Nagren, Kjell; Grehn, Leif; Langsfroem, Bengt; Ragnarsson, Ulf; J.Chem.SocPerkin Trans.1; EN; 1988; 497-502.
- Vinyl sulfones Horner, L.; Lindel, H.; Phosphorus Sulfur; GE; 15; 1983; 1- 8. 5 cu-Halo ketones: Silva, Claudius D'; Seddon, Andrew P.; Douglas, Kenneth
- Haloacetate Climie, Ian J. G.; Evans, David A.; Tefrahedron; EN; 38; 5; 1982; 697-711. 0 Unsaturated ketones: Spanton, Stephen G.; Prestwich, Glenn D.;
- Epoxide Jin, Lbda; Baillie, Thomas A.; Chem. Res. Toxicol.; EN; 10; 3; 0 1997; 318 - 327.
- a racemic mixture of a compound may be reacted o with an optically active resolving agent to form a pair of diastereoisomeric compounds.
- the diastereomers may then be separated in order to recover the optically pure enantiomers.
- Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts).
- Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, 5 solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities.
- diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility.
- separation/resolution techniques based upon differences in solubility.
- Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
- a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
- Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application.
- the salt forms of 0 the compounds can be prepared using salts of the starting materials or intermediates.
- the free acid or free base forms of the compounds can be prepared from the conesponding base addition salt or acid addition salt fonn.
- a compound in an acid addition salt form can be converted to the conesponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
- a suitable base e.g., ammonium hydroxide solution, sodium hydroxide, and the like.
- a compound in a base addition salt form can be converted to the conesponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).
- Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, hie. 1999.
- Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
- Compounds according to the present invention can also be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diasteromeric derivatives of compounds, dissociable complexes are prefened (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
- the diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
- the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or thee-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L- configuration unless otherwise noted. Unless otherwise noted, all starting materials are obtained from commercial suppliers and used without further purification. Synthetic Schemes For Renin Inhibitors of The Present Invention
- Renin inhibitors according to the present invention may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided herein in the examples. Other reaction schemes could be readily devised by those skilled in the art. hi the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry” John Wiley and Sons, 1991.
- a 10 mM solution of maleimidopropionylaminoethoxyethoxyacetyl derivatized peptide in DMSO is added to a 25% water solution of HSA.
- the final peptide concenfration in the reaction mixture is 1 mM and the molar ratio in reaction mixture of peptide: HSA is 1 : 1.
- the solution is incubated 5 hours at 37 °C. Once incubation is complete, the conjugate is stored at 4 °C.
- One method of measuring renin enzyme activity uses the cleavage of a synthetic peptide substrate in a fluorescence-based microplate reader.
- the peptide substrate for renin is linked to a fluorophore (5-(aminoethyl)aminonaphthalene sulfonate, EDANS) at one end and to a nonfluorescent chromophore (4 s - dimethylaminoazobenzene-4-carboxylate, DABCYL) at the other.
- a fluorophore 5-(aminoethyl)aminonaphthalene sulfonate, EDANS
- DABCYL nonfluorescent chromophore
- a 500 ⁇ M stock solution of renin substrate can be prepared by adding 877 ⁇ L of dimethyl sulfoxide (DMSO) to 1 mg of substtate. This stock solution is added into the assay buffer to a final concentration of 2 ⁇ M. A small amount ( ⁇ 3% of the final volume) of renin- containing solution is diluted in the assay buffer. The initial rate of cleavage of fluorogenic substrate is measures by monitoring the increase in fluorescence signal at 490 nm for 5-8 min at 37 °C. Our conjugates show activity from subnanomolar to high micromolar in this assay.
- DMSO dimethyl sulfoxide
- Plasma renin activity is determined based on method originally described by Haber et al. (1). Briefly, plasma samples are divided on two aliquots. One aliquot is 5 incubated for 3-18 h at 37 C, while another aliquot is kept on ice. The angiotensin I concenfration is determined using commercial kits in RIA or ELISA format according to manufacturer protocol. The angiotensin I concentration in the aliquot kept at 0-4 C is subtracted from that in 37 C aliquot to give a measure of renin activity. l o Activity of renin in plasma can also be measured towards externally added renin peptide substrate using HPLC separation of cleavage products. Cleavage products may be detected by LC-MS analysis. Alternatively, peptide substrate can be modified by fluorophore or chromophore to allow spectrophotometric detection. Plasma proteins can be removed by precipitation prior the HPLC analysis.
- Concentration of renin inhibitor and/or renin inhibitor-HSA conjugate in plasma is determined by enzyme-based assay (2), which measures inhibitory potential of plasma sample towards externally added recombinant human renin using commercially available quenched fluorescent substrate (3) at pH 7.0-8.0.
- Example 18 In vivo testing
- the conjugate is administered intravenously to rats.
- the inhibitor not conjugated with albumin is administered in a control group.
- Serum samples are collected at 5 min, 30 min, lh, 2h, 8h, 24h, 48h, and 72h post dose. Renin inliibitory activity is measured by one of the methods described above. Se m concentrations of peptide or peptide-HSA conjugates were calculated from the calibration curves. Based on results of these experiments the following conclusions maybe drawn:
- the control peptide displayed a clearance profile with rapid elimination. 5
- the terminal half-life of HSA conjugates range from 12 to 14 hours, similar to that of HSA in this species.
- Antihypertensive activity due to human renin inhibition can be measured in hypertensive rats doubly transgenic for human angiotensinogen with endogenous promoter and human renin with endogenous promoter, l o Bohlender, et al. Hypertension 428-434 (1997)
- Rabbit plasma is obtained from freshly drawn heparinized blood. One 8 mL aliquot of plasma is incubated with 5 micromoles of the Hi-L-Pr complex for 60 minutes at room temperature. Another equal aliquot is similarly incubated with 5 25 micromoles of the fli-L-Pr complex. The reaction mixtures are stored at 4 °C overnight. Aliquots of these samples are saved for analysis of total renin inhibitor content by a standard renin radioimmunoassay (RIA). After warming to 37 °C, the plasma samples are injected into two autologous rabbits. The rabbits are then bled at defined intervals.
- RIA renin radioimmunoassay
- Plasma proteins derivatized with the NHS ester of the Hi-L-Pr complex did indeed maintain the inhibitor in a conformation which remained bioavailable and inhibitory after an extended period of circulation in the blood. Again, the amount of inhibitor detectable has been normalized for the effect of 5 dilution of the plasma by the volume of blood in circulation.
- the modified plasma proteins as the Hi-L-Pr complexes are inhibitory in the renin assay, indicating that the conjugation did not destroy the bioactivity of the inhibitor Hi.
- the 0 level of the inhibition observed does not significantly decrease until day 10.
- Several abundant plasma proteins (albumin and immunoglobulins) are long-lived and could account for this delivery profile.
- the subject invention provides for greatly improved freatment involving renin inhibition Hi by the use of the complexes of Formula I and Formula U.
- the renin inhibitors Hi maintain for extended periods of time, so that repetitive dosages are not required, o compliance by the patient is not required, and protection is ensured.
- the derivatized renin inhibitors of the present invention covalently attach to erythrocytes, plasma proteins and various other vascular components to form the complexes of Formula I and Formula IL while retaining biological activity and are not immunogenic.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002520257A CA2520257A1 (en) | 2003-03-24 | 2004-03-24 | Long acting biologically active conjugates |
EP04758058A EP1620120A4 (en) | 2003-03-24 | 2004-03-24 | Long acting biologically active conjugates |
US10/550,715 US20070207952A1 (en) | 2003-03-24 | 2004-03-24 | Long Acting Biologically Active Conjugates |
JP2006507484A JP2006521361A (en) | 2003-03-24 | 2004-03-24 | Long-acting bioactive conjugate |
AU2004223829A AU2004223829A1 (en) | 2003-03-24 | 2004-03-24 | Long acting biologically active conjugates |
NZ543122A NZ543122A (en) | 2003-03-24 | 2004-03-24 | An HIV fusion inhibitor peptide covalently linked to a blood protein |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45647203P | 2003-03-24 | 2003-03-24 | |
US60/456,472 | 2003-03-24 | ||
US45695203P | 2003-03-25 | 2003-03-25 | |
US60/456,952 | 2003-03-25 | ||
US51889203P | 2003-11-10 | 2003-11-10 | |
US60/518,892 | 2003-11-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004085505A2 true WO2004085505A2 (en) | 2004-10-07 |
WO2004085505A3 WO2004085505A3 (en) | 2005-12-01 |
Family
ID=33101274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/008847 WO2004085505A2 (en) | 2003-03-24 | 2004-03-24 | Long acting biologically active conjugates |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070207952A1 (en) |
EP (1) | EP1620120A4 (en) |
JP (2) | JP2006521361A (en) |
KR (1) | KR20050120663A (en) |
AU (1) | AU2004223829A1 (en) |
CA (1) | CA2520257A1 (en) |
NZ (2) | NZ543122A (en) |
WO (1) | WO2004085505A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006108594A1 (en) * | 2005-04-08 | 2006-10-19 | Lonza Ag | Peptide synthesis of alpha-helixes on peg resin |
WO2009012944A1 (en) | 2007-07-20 | 2009-01-29 | F.Hoffmann-La Roche Ag | A conjugate of an antibody against cd4 and antifusogenic peptides |
US20100204142A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent |
US7951920B2 (en) | 2006-08-17 | 2011-05-31 | Roche Palo Alto Llc | Conjugate of an antibody against CCR5 and an antifusogenic peptide |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
JP4762889B2 (en) * | 2003-03-12 | 2011-08-31 | バスジーン セラピューティクス,インコーポレイテッド | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
KR20120123619A (en) | 2004-03-12 | 2012-11-08 | 바스진 테라퓨틱스, 인크. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
NZ549787A (en) * | 2004-03-12 | 2010-05-28 | Vasgene Therapeutics Inc | Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth |
WO2006034455A2 (en) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
GB201006038D0 (en) * | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
CA2796338C (en) * | 2010-04-13 | 2020-03-24 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
BR112013003671A2 (en) | 2010-08-18 | 2017-01-10 | Del Mar Pharmaceuticals | compositions and methods for improving the therapeutic benefits of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyl anhydrogalactiol |
EP3795145A3 (en) | 2011-08-17 | 2021-06-09 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
CN115778934A (en) | 2012-01-20 | 2023-03-14 | 德玛公司 | Use of substituted hexitols for the treatment of malignant tumors |
CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
US9814693B2 (en) | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
WO2014168986A1 (en) | 2013-04-08 | 2014-10-16 | Brown Dennis M | Therapeutic benefit of suboptimally administered chemical compounds |
AU2014293011A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene |
EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
TWI563001B (en) | 2014-08-22 | 2016-12-21 | Univ Nat Cheng Kung | Disintegrin variants and pharmaceutical uses thereof |
EP3661543A4 (en) * | 2017-07-31 | 2021-09-22 | The Trustees of Indiana University | Modified ddah polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses |
CN111053892B (en) * | 2019-12-24 | 2023-11-17 | 山西锦波生物医药股份有限公司 | Broad-spectrum enterovirus-resistant protein medicine and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1164239B (en) * | 1983-05-25 | 1987-04-08 | Anic Spa | A RETRO-REVERSE ANALOG OF THE DECAPEPTIDE (5-14) OF THE EQUINE ANGIOTENSINOGEN SPECIFIC INHIBITOR OF RENINE WITH HIGH RESISTANCE TO ENZYMATIC HYDROLYSIS |
IE873186L (en) * | 1986-12-23 | 1988-06-23 | Harvard College | Renin inhibitors iv |
AU2783189A (en) * | 1987-10-26 | 1989-05-23 | Warner-Lambert Company | Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
FR2650598B1 (en) * | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
DE19926475A1 (en) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Carrier-drug conjugates |
AU2002213843B2 (en) * | 2000-11-10 | 2008-02-07 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
DE10121982B4 (en) * | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation |
ES2277173T3 (en) * | 2001-05-31 | 2007-07-01 | Conjuchem Biotechnologies Inc. | LONG-LIFE FUSION PEPTID INHIBITORS AGAINST HIV INFECTIONS. |
-
2004
- 2004-03-24 AU AU2004223829A patent/AU2004223829A1/en not_active Abandoned
- 2004-03-24 NZ NZ543122A patent/NZ543122A/en not_active IP Right Cessation
- 2004-03-24 JP JP2006507484A patent/JP2006521361A/en active Pending
- 2004-03-24 NZ NZ567952A patent/NZ567952A/en not_active IP Right Cessation
- 2004-03-24 WO PCT/US2004/008847 patent/WO2004085505A2/en active Application Filing
- 2004-03-24 US US10/550,715 patent/US20070207952A1/en not_active Abandoned
- 2004-03-24 EP EP04758058A patent/EP1620120A4/en not_active Withdrawn
- 2004-03-24 CA CA002520257A patent/CA2520257A1/en not_active Abandoned
- 2004-03-24 KR KR1020057017965A patent/KR20050120663A/en not_active Application Discontinuation
-
2010
- 2010-07-05 JP JP2010153334A patent/JP2011006419A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP1620120A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006108594A1 (en) * | 2005-04-08 | 2006-10-19 | Lonza Ag | Peptide synthesis of alpha-helixes on peg resin |
US7951920B2 (en) | 2006-08-17 | 2011-05-31 | Roche Palo Alto Llc | Conjugate of an antibody against CCR5 and an antifusogenic peptide |
WO2009012944A1 (en) | 2007-07-20 | 2009-01-29 | F.Hoffmann-La Roche Ag | A conjugate of an antibody against cd4 and antifusogenic peptides |
EP2526972A1 (en) | 2007-07-20 | 2012-11-28 | F. Hoffmann-La Roche AG | A conjugate of an antibody against CD4 and antifusogenic peptides |
US20100204142A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent |
Also Published As
Publication number | Publication date |
---|---|
KR20050120663A (en) | 2005-12-22 |
NZ567952A (en) | 2009-12-24 |
JP2011006419A (en) | 2011-01-13 |
WO2004085505A3 (en) | 2005-12-01 |
JP2006521361A (en) | 2006-09-21 |
EP1620120A4 (en) | 2010-01-06 |
EP1620120A2 (en) | 2006-02-01 |
US20070207952A1 (en) | 2007-09-06 |
CA2520257A1 (en) | 2004-10-07 |
NZ543122A (en) | 2008-07-31 |
AU2004223829A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070207952A1 (en) | Long Acting Biologically Active Conjugates | |
JP5537431B2 (en) | Cholesterol derivatives of inhibitors of virus fusion | |
JP2023025151A (en) | Multi-ligand-drug conjugates and uses thereof | |
US20120040891A1 (en) | Hiv fusion inhibitor peptides with improved biological properties | |
JP2007529522A (en) | Site-specific chemical modification of HIV gp41-derived peptide | |
WO2006105201A2 (en) | Conjugates comprised of fatty acid and hiv gp41-derived peptide | |
WO2018191858A1 (en) | Potent hiv inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof | |
EP3399994B1 (en) | D-peptide inhibitors of hiv entry and methods of use | |
ZA200508190B (en) | Long acting biologically active conjugates | |
US20020022027A1 (en) | Compositions and methods for delivery of a molecule into a cell | |
US20190375792A1 (en) | Cyclic Peptide Antiviral Agents and Methods Using Same | |
JP4332618B2 (en) | Anti-HIV agent | |
US20230355708A1 (en) | Compositions for inhibiting viral entry and methods using same | |
EP3872084A1 (en) | Epi-x4 based peptides and derivatives thereof | |
TW200427697A (en) | Pegylated t1249 polypeptide | |
Kadow et al. | Protein-protein interaction targets to inhibit HIV-1 infection | |
MXPA06009352A (en) | Site-specific chemical modification of hiv gp41-derived peptides | |
ZA200500257B (en) | Pegylated T1249 polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020057017965 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2520257 Country of ref document: CA Ref document number: 2006507484 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/08190 Country of ref document: ZA Ref document number: 2004758058 Country of ref document: EP Ref document number: 200508190 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004223829 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 543122 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004223829 Country of ref document: AU Date of ref document: 20040324 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004223829 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048140552 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057017965 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004758058 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007207952 Country of ref document: US Ref document number: 10550715 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10550715 Country of ref document: US |